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“The height of sophistication is simplicity.” 
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2. Scientific environment 
The present research project was performed within the Bergen Hypertension and 
Cardiac Dynamics group at the Department for Clinical Science, University of 
Bergen, Norway, through the years 2014-2020. The first part was conducted through 
the Medical Student Research Program at The Faculty of Medicine, and continued 
through the Ph.D. program at the University of Bergen from 2018-2020. 
The Bergen Hypertension and Cardiac Dynamics Group is chaired by 
Professor Eva Gerdts. The group consists of two additional Professors, one post-
doctoral fellow, six PhD-fellows, one research medical student, technicians, study 
nurses and several consultants in cardiology employed at the Department of Heart 
Disease, Haukeland University Hospital, who also work closely with the group. The 
Bergen Hypertension and Cardiac Dynamics Group is focused on non-invasive 
cardiac imaging methods in clinical and experimental studies, with echocardiography 
as the main scientific tool. The group is responsible for the Echocardiography 
Research Laboratory, which is a state-of-the-art laboratory for echocardiographic 
image analysis. The core fields of interest are valvular heart disease, hypertensive 
heart disease and sex differences in cardiovascular disease. The group has a large 
collaborating network that extends both nationally and internationally.   
 A collaboration with the Department of Clinical Pharmacology, British Heart 
Foundation Centre of Research Excellence, King's College London, through 
Professor Phillip J. Chowienczyk, Professor John B. Chambers and senior researcher 
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AS Aortic valve stenosis 
AT/ET Acceleration /ejection time 
AVA Aortic valve area  
AVR Aortic valve replacement 
β Standardized beta coefficient  
BMI Body mass index  
CI Confidence interval 
CV Cardiovascular 
EF Ejection fraction 
EF1 First phase ejection fraction  
GAM Generalized additive model 
HF Heart failure 
HR Hazard ratio  
LV Left ventricular/Left ventricle  
NRI Net reclassification index  
OR Odds ratio 
PLGAS Paradoxical low gradient severe aortic stenosis 
PP/SVi Pulse pressure/stroke volume index 
RWT Relative wall thickness 
S` Peak systolic annular velocity 
SEAS  Simvastatin Ezetimibe in Aortic Stenosis 






Background: Aortic valve stenosis (AS) is the most prevalent valvular heart disease 
requiring valvular intervention. With no pharmacological treatment available, optimal 
management requires detection of early left ventricular (LV) systolic dysfunction, 
accurate grading of AS severity and identification of risk factors associated with 
residual cardiac damage after aortic valve replacement (AVR). This thesis aimed to 
address these concerns.  
 
Material and methods: This thesis include three papers based upon two different 
cohorts. In Study 1, we prospectively included 120 patients with mild, moderate and 
severe AS in a cross-sectional study to investigate the covariates of the first-phase 
ejection fraction (EF1), a novel marker of peak systolic function in AS. In Study 2 we 
included 1530 patients with asymptomatic non-severe AS from the Simvastatin and 
Ezetimibe in Aortic Stenosis (SEAS) study to evaluate the prognostic impact of 
increased acceleration ejection time (AT/ET) ratio on cardiovascular (CV) outcome 
during progression of AS. In study 3, we explored the association between 
preoperative obesity and persistent LV hypertrophy after AVR in 399 patients who 
developed severe AS during follow-up in the SEAS study.   
 
Results: In Study 1, EF1 was associated with lower strain rate, a marker of 
myocardial contractility, and higher pulse pressure/stroke volume index, a surrogate 
of arterial stiffness, independent of AS severity. EF1 declined from mild to severe 
AS, while EF remained similar across groups. In Study 2, higher AT/ET ratio was an 
independent predictor of poor outcome in the total study population and among 
patients with discordantly graded AS. An AT/ET ratio >0.32 was found to be the best 
cut-off to predict CV death and heart failure (HF) hospitalization among patients with 
discordantly graded AS. In Study 3, preoperative obesity was strongly associated 
with persistent LV hypertrophy after median a 6 months follow-up 6 after AVR. In 
multivariable analysis, this association was independent of lower myocardial function 




Conclusion: In patients with varying degree of AS severity in Study 1, lower 
myocardial contractility and higher arterial stiffness were both independently 
associated with lower EF1. In Study 2, higher AT/ET ratio was associated with 
increased CV morbidity and mortality independent of traditional risk markers. Higher 
AT/ET ratio seemed especially useful in patients with discordantly graded AS, 
beyond conventional grading.  Lastly, in Study 3, obesity was found to be 
independently associated with higher prevalence of LV hypertrophy, an important 
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The aetiology of aortic valve calcification as a cause of aortic valve stenosis (AS) was 
first described by Mönckeburg in 1904.1 He proposed that pathologically calcium 
depositions on the aortic cusps would lead to valve sclerosis. AS denotes the 
narrowing of the aortic valve opening. Since Mönckeburg the cause of AS has been 
known to be either congenital or acquired. The latter being further classified into 
rheumatic or degenerative. Even though sequelae from rheumatic fever constitute a 
considerable portion of AS in developing countries, the decline in rheumatic fever 
and increasing life expectancy has made degenerative calcification by far the most 
common cause of AS worldwide.2-4 The current work is focused on degenerative AS, 
and further mentioning of AS will thus not include rheumatic or congenital AS. 
7.1 Prevalence of AS 
Aortic valve sclerosis represents focal thickening of the valvular cusps without 
significant obstruction of blood flow. Aortic valve sclerosis is fairly common in the 
general population, with an expected prevalence around 25% in those 65 years or 
older and almost 50% in those 85 years or older.5,6 From population based studies it 
has been estimated that only a minority, approximately 9%, of subjects with aortic 
valve sclerosis progress to AS over a five year period.7,8 Like valve sclerosis, AS is 
mainly a disease encountered among the elderly, and the prevalence increases sharply 
with age.9 Different studies have reported a frequency of approximately 3-5% in 
those over 65 years, and in 10% of octogenarians in the Tromsø study.5,6,9,10 After 
coronary artery disease and hypertension, AS is the third most frequent 
cardiovascular (CV) disease.11 Additionally, AS has become the most common valve 
disease requiring surgical intervention.3 Also, the prevalence of AS is expected to rise 




7.2 Progression of AS 
Based on a observational study by Otto et al. it has been estimated that the yearly 
progression rate of valve severity increases by approximately 0.3 m/s in transaortic 
velocity, by 7 mm Hg in mean transaortic pressure gradient and with a reduction of 
0.1cm2 in aortic valve area(AVA).12 However, there are significantly individual 
differences and some subgroups may experience either a faster or slower 
progression.13 In the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study, 
investigating mild and moderate AS patients without overt CV disease, the yearly 
progression rate was found to be lower; increase in transaortic velocity by 0.15 m/s, 
in mean transaortic pressure gradient by 2.8 mm Hg/year and a reduction in AVA by 
0.03 cm2/year.14 
AS patients are usually asymptomatic for many years. Symptom-onset may 
represent an arbitrary timepoint as initial symptoms may be vague and unspecific due 
to the progressive nature of the disease. Additionally, many patients may adhere to a 
sedentary lifestyle due to aging or comorbidities, which may conceal apparent 
symptoms such as exertional dyspnea and reduced exercise capacity. However, the 
onset of cardinal symptoms such as dyspnea, angina and syncope have a grim 
prognosis without intervention.15 With no pharmacological treatment proven to 
attenuate or prevent the sclerotic process, the only available treatment options are 
either surgical aortic valve replacement(AVR) or transcatheter valve replacement.16,17 
Left untreated symptomatic patients face a two-year mortality rate of up to 50% when 
treated conservatively.18,19 The effect of development of symptoms on mortality was 
first documented by Braunwald and Ross in their seminal paper from 1968.15 Even 
today, the presence or absence of symptoms are critical for appropriate management 
of patients. The current guidelines recommend valvular intervention mainly in 
patients with severe symptomatic AS, in patients with severe AS and reduced LV 
function, or in moderate AS when presence of other cardiac diseases requires open 
heart surgery.16,17 
Whilst older studies implied that non-severe AS should be regarded as benign, 




term prognosis.20 Rosenhek et al. demonstrated that mortality was 1.8 times higher in 
patients with mild to moderate AS compared to an age and gender matched 
population.13 The Cardiovascular Health Study reported that even individuals with 
aortic sclerosis, without known coronary artery disease, had 1.4 times higher risk of 
myocardial infarction than those without aortic sclerosis.21 Recent studies challenge 
current practice by demonstrating that subgroups of AS patients, currently not 
deemed eligible for valvular intervention by the current guidelines, may have 
similarly prognosis as severe symptomatic AS without valvular replacement.22,23 New 
and better tools for identification of the optimal timing of valvular replacement are 
necessary to improve patient outcomes. The challenge remains to better identify high-
risk patients where the risk of valve replacement outweighs the risk of conservative 
treatment for long-term prognosis. Thus, novel markers of early LV systolic 
dysfunction, additional measures to accurately grade AS and integrated CV risk 
factor management are needed.  
7.3 LV systolic function in AS 
Ejection fraction (EF) is the most commonly used measure of left ventricular (LV) 
systolic performance in AS. Assessment of transvalvular flow by stroke volume index 
(SVi) by Doppler is used to subdivide into different flow gradient patterns based 
upon a low flow state (SVi<35ml/m2). The current guidelines regard EF<50% as a 
class 1 indication for valvular replacement in patients with severe symptomatic 
AS,16,17 although the lower gender-specific values for normal LV EF is 52% in men 
and 54% in women, respectively.24 In truly asymptomatic patients the prevalence of 
EF<50% may be as low as below 1%, despite reduced LV systolic function when 
assessed by other methods.25,26 Furthermore, a particular ambiguity exist in patients 
with EF >50% and a flow gradient pattern of low gradient severe AS with either 
reduced or normal flow, which may have increased risk compared to other subtypes 
of AS with EF >50%.27 These patients may have severely elevated afterload, but also 
reduced LV function when assessed by global longitudinal strain.28 An EF >50% with 




recruitment of preload reserve or a compensatory increase in circumferential 
shortening which may maintain SV and EF even with reduced long-axis function.29-31 
This underlines that the traditional 50% EF cut-off is not sufficient to detect subtle 
changes in LV function which may portray early systolic dysfunction. Some have 
proposed using a EF threshold of 60%,32 whereas other highlight the limitation of EF 
as a marker of contractility in LV hypertrophy.33,34 Additional measures of systolic 
function, like midwall fractional shortening and myocardial strain, have been 
developed and documented to be more sensitive in detection of early LV systolic 
dysfunction.35-37 In patients with severe AS and preserved EF(>50%), lower global 
longitudinal strain was shown to be more sensitive in predicting CV events compared 
to EF.38 Recently, lower global longitudinal strain was also associated with higher 
mortality rates in patients with moderate AS and preserved EF.39 However, global 
longitudinal strain is, similar to EF, significantly afterload dependent.40 This 
represents an inherent problem in AS which is characterized by a high afterload. 
There is also lack of a universal cut-off value which may be used to discriminate 
between high-and low risk individuals, mainly due to inter-vendor variabilities in 
strain algorithms, and a wide range between proposed cut-offs in different studies.41,42 
Measures of peak systolic function, such as strain rate, may also be measured by 
speckle tracking echocardiography. Strain rate is more related to contractility than 
strain and less influenced by changes in cardiac load. However, it is not widely used 
in clinical practice, mainly because of limited temporal resolution.43,44 In clinical 
practice, measurement of strain rate may be considered time consuming. A marker of 
LV function that relates more to peak systolic function and is easy to measure would 
therefore be of interest.  
7.4 Peak LV systolic function 
Given the prognostic implications on development of LV systolic dysfunction, 
detection of early myocardial dysfunction may offer the potential to optimize timing 
of intervention and thereby improve patient outcomes. The first-phase EF (EF1) has 




described as the “FEV1 of the heart”.45 EF1 represents the LV EF measured at the 
time of peak aortic jet velocity.46 Biophysics of cardiomyocytes suggests that 
regulation of myocyte contraction through mechanosensing may preserve overall 
contraction but at the expense of a slower and sustained contraction.47,48 Previous 
studies have shown that EF1 is impaired in patients with hypertension and diastolic 
dysfunction and in patients with AS with preserved EF.46,49 EF1 was also shown to 
predict adverse outcome in patients with AS better than end-systolic markers, 
including global longitudinal strain.49 
EF1 as a measure of peak systolic function may therefore be a more sensitive 
measure of early dysfunction than end-systolic markers like EF and global 
longitudinal strain in patients with AS. Theoretically, EF1 should occur at the time of 
maximal myocardial contraction. However, the association between EF1 and other 
markers of peak systolic function have not been reported. In particular, more 
knowledge about the association between EF1 and strain rate, a measure closely 
related to myocardial contractility,43 would be of interest.   
7.5 Ejection dynamics  
Current markers of AS severity are clearly insufficient to identify all high-risk 
individuals. In particular, evaluation of AS severity remains challenging when 
conventional grading by peak aortic jet velocity, mean transaortic pressure gradient 
and AVA results in discordant grading, i.e. graded as moderate AS by peak jet 
velocity and mean valve gradient, but graded as severe by AVA. Often this situation 
occurs in patients with a reduced LV EF (<50%), which is termed low-flow low-
gradient AS when SVi is <35 ml/m2. A discordant grading in patients with normal EF 
(>50%), termed paradoxical low gradient severe AS (PLGAS), is a particularly 
challenging entity.50 Accurately assessing AS severity in patients with moderate AS, 
and especially in patients with PLGAS, remains difficult when adhering to the current 
guidelines. Doppler measurements of peak aortic jet velocity and transaortic pressure 
gradient are highly angle-dependent, and the use of the continuity equation is prone to 




overestimation of the orifice area.51 Ejection dynamics on the other hand, are less 
angle-dependent and reliable measurements which may provide incremental 
information in patients with native AS. It is well known from older studies that severe 
AS has a slow up stroke and an aortic jet with a rounded contour.52 However, the 
utility of the acceleration/ejection time (AT/ET) ratio was first evaluated in patients 
with prosthetic valves by Zekry et al., and is currently implemented in the evaluation 
of prosthetic valve function.53,54 In smaller studies on native severe AS, an increased 
AT/ET ratio has been independently associated with increased mortality.55,56 The 
associations between higher AT/ET ratio and LV systolic function and prognosis have 
not been reported in patients with non-severe AS. Furthermore, whether assessment 
of ejection dynamics may improve identification of high-risk individuals among 
patients with PLGAS needs further exploration. 
7.6 Obesity and LV hypertrophy after AVR 
Worldwide the prevalence of obesity has nearly doubled from the 1980 to 2017 and is 
expected to rise further in the coming years, especially in women.57 With an 
inevitably higher prevalence of AS due to longer life expectancies and an aging 
population, the potential importance of obesity on AS management and outcome will 
increase. 
Following AVR an abrupt alleviation of the LV overload leads to a reduction in 
LV pressure and afterload. Normalization of LV geometry is expected after 
successful AVR in AS, but does not occur in all patients despite appropriately sized 
aortic valve prostheses.58 Lack of normalization of LV hypertrophy has been 
documented to be associated with poor long-term postoperative prognosis.59 In a 
prospective study following LV mass regression in patients operated with AVR for 
AS, regression of LV hypertrophy was dependent on the preoperative risk profile.60 
This highlights that understanding the underlying factors contributing to lack of 
normalization of LV hypertrophy is of utter importance. It is well known that severe 
patient-prosthetic mismatch, uncontrolled blood pressure and systemic hypertension 




Previous data from our group have shown that obesity increases LV mass during 
progression of AS.64 Obesity has also been implicated as a risk factor for many 
predisposing conditions for CV disease such as hypertension, diabetes and 
atherosclerosis.65. Interestingly, new data from large epidemiologic studies with 
mendelian randomization design suggests that obesity might be causally associated 
with higher risk of developing AS.66,67 In similar studies with over 100.000 
participants from the general population, plasma triglycerides, remnant cholesterol 
and low-density lipoprotein, important components of the metabolic syndrome, have 
been associated with higher risk of incident and symptomatic AS.68,69 Even though 
obesity has been extensively studied as a risk marker for CV disease in general and 
during progression of AS, less is known about the effect of obesity on normalization 
of LV structure and function after AVR. Thus, more knowledge on the influence of 








We hypothesized that measures of peak systolic function and LV ejection 
dynamics could be useful in detection of high-risk AS patients beyond 
conventional measures. Secondly, we hypothesized that obesity would be 




8.1.2 Specific aims  
1. Identify covariates of peak LV systolic function measured by EF1 in patients 
with mild, moderate and severe AS. 
 
2. Assess the impact of LV ejection dynamics measured by AT/ET ratio on CV 
outcome in patients with non-severe AS. 
 
3. Investigate the effect of preoperative obesity on persistent LV hypertrophy after 









9.1 Study design and patient population 
9.1.1 Study 1 
Study 1 is a prospective cross-sectional study which was conducted to test the 
associations between EF1, myocardial contractility and arterial function. A total of 
120 study participants were recruited from the Department of Heart Disease, 
Haukeland University Hospital between October 2015 and December 2017. Inclusion 
criteria were aortic valve thickening on echocardiography and at least mild AS, 
defined in accordance with the current AHA/ACC guidelines at the time of 
inclusion.17  Patients were excluded if they met one of the predefined exclusion 
criteria: cardiac arrhythmias, prior pacemaker implantation, other concomitant 
valvular disease of more than moderate grade, known coronary artery disease 
(myocardial infarction, coronary artery bypass grafting or percutaneous coronary 
intervention) or previous cardiac surgery. For the present study, three patients were 
excluded from the analysis due to EF <50% and another three patients due to poor 
image quality not suited for reliable analysis of EF1. Thus, 114 patients with mild, 
moderate or severe AS were included in the final analysis (Figure 1). Written 
informed consent was obtained from all study participants. The study was approved 
by the local Regional Committee for Medical and Health Research Ethics (approval 
number 2014/1895/REK Nord) and was conducted in accordance with the 












Figure 1. Flow chart of patients included in Study 1.  
 
 
9.1.2 Study 2 and 3 
Study 2 and 3 were based on data from the SEAS study. The SEAS study included 
1873 participants aged 45-85 years with asymptomatic mild-and moderate AS 
(thickened aortic valve cusps and peak aortic jet velocity ≥ 2.5 and ≤ 4 m/s).14 
Patients were randomized to double blind, placebo-controlled lipid lowering 
treatment with combined simvastatin 40 mg and 10 mg ezetimibe. Study participants 




2002-4 and were followed up at a minimum of 4 years (median 4.3 years). Patients 
with coronary artery disease, peripheral vascular disease, previous stroke, history of 
diabetes, systolic heart failure (HF), other significant valvular disease, renal 
insufficiency or any other condition requiring lipid lowering treatment were excluded 
from the study.70 A detailed description including study protocol, design and patient’s 
recruitment has been previously published.70 The study protocol was approved by 
regional ethics committees in all participating countries, and informed consent was 
obtained from all patients. The study was registered online at www.clinicaltrials.gov 
with identifier NCT00092677.  
In SEAS, a total of 1772 patients had data on AT/ET ratio on the baseline 
echocardiogram (95%). Some of the patients included in SEAS as moderate AS by 
their attending physician were documented to have severe AS after core laboratory 
reading of the images (peak aortic jet velocity ≥ 4.0 m/s). For Study 2, these patients 
were excluded (n=107). Additionally, patients with EF < 50% were excluded from 
the final analysis (n=135)(Figure 2). Study 2 therefore included 1530 patients.  
Study 3 was a post hoc analysis of data from  SEAS patients who underwent 
AVR during a median of 4.3 years follow-up. A total of 545 SEAS patients 
developed severe AS and were referred to AVR by the local study site physician. 
Among these patients, post-AVR echocardiograms were sent for expert interpretation 
at the core laboratory in 456 patients. 57 of these patients were excluded due to poor 
acoustic window in parasternal views, on either the pre-or post AVR echocardiogram. 
This yielded 399 SEAS patients with measurements of LV mass both at the pre-and 












Figure 2. Flow chart of study participants in Study 2 and 3. 
 
9.2 Echocardiography 
9.2.1 Protocol and analyses 
In Study 1, all patients were examined with two-dimensional transthoracic 
echocardiography following a standardized protocol using a Vivid E9 ultrasound 
scanner (GE Vingmed Ultrasound, Horten, Norway). All images were digitally stored 
and analyzed using an offline digital workstation (TomTec Imaging Systems GmbH, 
Unterschleissheim, Germany). All readings were done blinded to clinical and 
demographic data. Examinations were first read by the first author (EE) and later 




For Study 2 and 3, echocardiograms were obtained at the 173 local SEAS study 
sites with second harmonic imaging following a standardized protocol. All images 
were recorded and submitted to the Echocardiography Core Laboratory either by 
Video Home System videotapes, compact discs or magnetic optical disks for blinded 
expert interpretation. The inclusion of patients were decided by the local study site 
according to local measurements. Consequently, the study included some participants 
deemed outside the initial inclusion criteria (peak aortic jet velocity ≥ 2.5 and ≤ 4.0 
m/s) by the echocardiography core laboratory analysis. In Study 2, all baseline 
examinations were initially read by a junior member of the staff, and thereafter proof 
read by an experienced reader (EG). In Study 3, all post-AVR examinations were first 
read by the first-author (EE) and quality assured by the last-author (EG). In both 
studies, all readings were performed offline using a digital workstation equipped with 
Image Arena (TomTec Imaging Systems GmbH, Unterschleissheim, Germany) 
software. In Study 1, we assessed global longitudinal strain and strain rate by speckle 
tracking echocardiography. Global longitudinal strain and strain rate were measured 
offline on a dedicated workstation equipped with EchoPac BT 202 (GE Vingmed 
Ultrasound, Horten, Norway) software, following current recommendations.71 The 
analyses were performed by a single investigator (EE) and later quality assured by 
experienced readers (KM, SS). 
9.2.2 Evaluation of LV mass and geometry  
LV dimensions and wall thicknesses were measured in two-dimensional parasternal 
long-axis views following the current guidelines.72 LV mass was calculated by the 
Devereux’s formula that was validated against necropsy findings in a wide range of 
cardiac conditions:73 
 
LV	mass(g) = 0.8 × (1.04[(LVEDD + PWTD + IVSDD): − (LVEDD):]) + 0.6g 
 
in which LVEDD = LV end-diastolic inner diameter, PWTD = posterior end-diastolic 
wall thickness, IVSDD = interventricular septum end-diastolic wall thickness. LV 
mass was indexed for height in the allometric power of 2.7 to account for the 




overweight and obese subjects.74 LV hypertrophy was considered present if LV mass 
index exceeded the gender-specific, prognostically validated cut-off values of >46.7 
g/m2.7 in women and >49.2 g/m2.7 in men, respectively.74 Relative wall thickness 







and considered increased if ≥ 0.43.72 LV geometry was classified based on combined 
assessment of LV RWT and LV mass index into four different LV geometric groups 
in accordance with the guidelines.72 Normal LV geometry was defined as normal LV 
mass index by the aforementioned gender-specific values, and RWT <0.43. 
Concentric remodeling was considered present if LV mass was normal and RWT was 
abnormal (≥ 0.43). Eccentric hypertrophy was defined by the presence of LV 
hypertrophy and RWT <0.43, while concentric hypertrophy by presence of LV 
hypertrophy and abnormal RWT (≥ 0.43) (Figure 3). 





9.2.3 Systolic function  
Conventional LV EF was assessed at the endocardial level by the modified Simpsons’ 
biplane method of discs.72 In all studies, EF was considered low if <50% in both 
sexes in accordance with guidelines on AS.75 Additionally, LV systolic function was 
assessed at the myocardial level by calculation of midwall shortening (MWS).35 
MWS considers the epicardial migration of the midwall during systole, and is 













In the equation, Hs is the estimated LV inner myocardial thickness at end-systole.  
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To account for afterload dependent systolic function, midwall shortening was 
adjusted for circumferential end-systolic stress, as validated in hypertensive 
patients.76 Circumferential end-systolic stress was estimated at midwall assuming a 
cylindrical model as described by Gaasch et al.77,78 In the calculation of 
circumferential end-systolic stress, the mean aortic transvalvular pressure gradient 
was added to the brachial systolic blood pressure in the equation to allow for a more 
precise estimation of LV systolic pressure. Stress-corrected midwall shortening was 
then derived by the ratio of predicted to observed midwall shortening, adjusted for 
end-systolic stress. Stress-corrected midwall shortening was thus regarded as a 
relatively afterload independent marker of LV systolic function in Study 1 and 2.  
 









CESS = Circumferential end-systolic stress, ScMWS = stress-corrected midwall 
shortening. 
 
Systolic flow status was estimated by Doppler stroke volume, corrected for body 
surface area. Low-flow was defined as a SVi (<35 ml/m2), and normal-flow when 
above this threshold. 75 
Global longitudinal strain and strain rate 
Myocardial deformation can be assessed by the concept of strain.79 Strain is defined 
as the fractional change of tissue length compared to its original length. It is usally 
expressed as negative percentage shortening.80 Longitudinal strain during systole(ε) is 






Where L is the length at a given point in time, and L0 is the reference length at end-
diastole.   
 
Myocardial deformation can be measured in the 3 chamber directions, 
longitudinal, circumferential and radial direction, as well as twist and rotation. 
Longitudinal strain is an index of the long axis function of LV. Strain rate (s-1) on the 
other hand, is the first derivative of strain with respect to time, and describes the 
speed of deformation in the myocardium during the cardiac cycle.81  
A method to measure strain is by the use of Speckle Tracking 
Echocardiography.80,82 Briefly, speckles are the results of random scattering from 
small reflectors and the interference between this scattering from several ultrasound 
beams. Speckles are relatively stable during the cardiac cycle and can be grouped into 
kernels within a region of interest. These kernels can then be tracked during the 
cardiac cycle. Speckle tracking echocardiography has been validated against both 
microsonometry and magnetic ressonance imaging.83 Global longitudinal strain is the 
most widely used and reproducible measure of strain, and is less affected by 




In Study 1, global longitudinal strain was defined as the average of peak 
systolic negative longitudinal shortening from 18 LV segments from the apical four-
chamber, two-chamber and long-axis views (Figure 5). The onset of contraction was 
defined as the first deflection of the QRS-complex on the electrocardiogram 
recording. End-diastole was defined from aortic valve closure from a pulsed wave 
Doppler recording with similar heart rate as the images used for strain analyses. All 
images were carefully optimized to achieve an adequate frame rate / heart rate ratio 
>1(median 74 frames/s, mean 73 frames/s). Strain rate was derived automatically 
from the strain curves as the first derivative in each segment, and then averaged to 
obtain peak systolic strain rate 
 
Figure 5. Typical example of global longitudinal strain by speckle 
tracking measured from a apical three-chamber view. 
 
 
Acceleration/Ejection time ratio  
In Study 1 and 2, AT/ET ratio was calculated by assessment of the timing intervals 
from a continuous spectral Doppler recording of the aortic jet velocity. AT time was 
defined as the time in milliseconds from aortic valve opening to peak aortic jet 
velocity. The ET was defined as the time in milliseconds from opening to closure of 












Figure 6. Measurement of AT/ET ratio from a continuous wave 













In Study 1, EF1 was measured manually by the biplane method of discs by measuring 
the volume change from end-diastole to the time that corresponded to peak aortic jet 







EDV= end-diastolic volume. V1 = volume at the peak aortic jet velocity (Figure 7). 
 
We calculated the exact frame in which to measure EF1. This was done by first 
measuring the time in milliseconds(ms) from the R-wave on electrocardiogram 
recordings from the Doppler signal to peak aortic jet velocity. With a simple in 
custom-made program, the exact frame of EF1 on B-mode images was derived by 
multiplying the frame-rate with the time to peak aortic jet velocity (Figure 7): 
 




Frame 0= the starting frame that matches the peak of the R-wave on the B-mode 
image. 
 
Due to the importance of timing for exact EF1 analysis, images with 
inadequate quality or frame rate were discarded. Adequate framerate was defined as 
framerate/heartrate ratio equivalent to or above one. Only images with a heartrate 
with equal or ± 10% difference between Doppler and B-mode images were chosen. 
EF1 was measured separately on a workstation equipped with EchoPac BT 202 (GE 
Vingmed Ultrasound, Horten, Norway) sofware. All measurements were performed 

















9.3 LV diastolic function  
In Study 2, diastolic dysfunction was defined in accordance with the current 
guidelines,85 if at least three of the following parameters were present: reduced 
annular è velocity by tissue Doppler (septal é <7 cm/s or lateral é <10cm/); filling 
pressure >14, defined as early transmitral E-wave/average mitral annular velocity 





9.4 Assessment of AS  
In Study 2 and 3, AS severity was graded in accordance with the joined European 
Association of Echocardiography and American Society of Echocardiography 
guidelines on management of valvular heart disease at the time of the SEAS study 
completion (Table 1).86 In Study 1, the current American College of 
Cardiology/American Heart Association guidelines was used, which includes those 
with a peak velocity of  2.0-2.9 m/s as mild AS.17  
 




Peak aortic jet velocity was measured by continuous wave Doppler in several 
acoustic windows (apical, right parasternal and suprasternal view). The highest aortic 
jet velocity acquired from any acoustic window was used for the tracing of the time 
velocity integral. The mean transaortic pressure gradient was obtained from the 
velocity time integral curve by tracing the outer edge of the Doppler flow. In patients 


















AVA=aortic valvular area. CSA=cross sectional area. LVOT=left ventricular outflow 
tract. VTI= velocity-time integral. AS= aortic valve stenosis. 
 
Patients with discordant grading (mean transaortic pressure gradient<40mmHg 
and AVA<1.0 cm2) were in Study 3 further assessed by low flow (SVi<35 ml/m2), 
which yielded two different flow gradient patterns, low flow low gradient and normal 
flow low gradient. In Study 3 these were grouped together as PLGAS. This was not 
assessed in Study 1 due to insufficient statistical power to investigate differences 
between flow gradient patterns.  
 
Arterial stiffness and global LV load 
Arterial stiffness was estimated by the ratio from a central pulse pressure (PP)/SVi. 
Central PP was estimated from brachial PP using a validated formula: brachial PP x 
0.49 + age x 0.30 +7.11.87 
Valvulo-arterial impedance (Zva) has been proposed as a surrogate measure of 
combined valvular and arterial load imposed on the LV during ejection. As 
appropriate, we calculated Zva as the sum of systolic blood pressure and mean 
transaortic pressure gradient divided by SVi.88  
9.5 Cardiovascular risk factors  
9.5.1 Blood pressure and hypertension 
In all studies, clinic blood pressure was measured as recommended by the current 
guidelines.89 Clinic and post-echocardiography blood pressure were measured both at 
baseline and at the last study visit before AVR in the SEAS study. Data were 
forwarded to the SEAS echocardiography core laboratory after study completion by 
the SEAS sponsor, Merck Schering Plough. Clinic blood pressure was measured by a 
standardized procedure with an appropriate cuff for the individual patient. Blood 
pressure measurement was performed with the patient in sitting position after five 
minutes initial rest. Blood pressure was measured in triplicates by a calibrated 




measurements was taken as the clinic blood pressure. Supine blood pressure was 
measured immediately after completion of the echocardiographic examination when 
the room was still dark, and with the patient in a supine position. Post-
echocardiographic blood pressure was used for calculations of hemodynamic 
variables. In all studies, hypertension was defined as combined history of 
hypertension, elevated clinic blood pressure (≥140/90 mmHg) and/or use of 
antihypertensive treatment.  
9.5.2 Overweight and obesity 
Body mass index (BMI) was derived from body weight in kilograms divided by 
height in meter squared in all studies. The criteria from the World Health 
Organization were used to classify patients into normal weight (BMI <25.0 kg/m2), 
overweight (BMI 25.0 kg/m2 – 29.9 kg/m2) and obesity (BMI ≥30.0 kg/m2)  
9.6 Endpoints in the SEAS study.  
All study endpoints in the SEAS study were adjudicated by an independent 
committee.70 The primary endpoint in the SEAS study was major CV events, a 
composite which included AS-related events (AVR, death from CV causes and 
congestive HF due to AS progression) and ischemic CV events (combined death from 
CV causes, non-fatal myocardial infarction, coronary artery revascularization, 
hospitalization for unstable angina and non-hemorrhagic stroke). All-cause mortality 
was considered as a tertiary endpoint. In Study 2, we assessed the associations 
between higher AT/ET ratio with the primary study endpoint, with CV death and HF 
hospitalization and with all-cause mortality. The latter endpoints were considered 
harder, or more objective endpoints compared to the primary study endpoint which 
was driven mainly by referral for AVR, based upon decision at local study sites. In 
Study 2 the endpoints CV death and HF hospitalization were combined to achieve 




9.7 Statistics  
Statistical analyses were performed using Statistical Package for Social Sciences 
version 24.0-25.0 (IBM Corporation, Armonk, NY, USA) and R version 3.6.1(The R 
Foundation for Statistical Computing, Vienna, Austria). Normal distributed data are 
expressed as mean ± standard deviation and non-normally. In Study 1, the 
participants were grouped according to AS severity by peak aortic jet velocity. In 
Study 2, according to the quartiles of AT/ET ratio. In Study 3, BMI was used to 
define obesity, and to divide the study population into BMI classes: normal weight 
(BMI < 25 kg/m2), overweight (BMI ≥25 kg/m2 and <30 kg/m2) and obesity (BMI 
≥30 kg/m2). Comparisons between groups were done with analysis of variance 
(ANOVA) with Scheffes`s post-hoc test for continuous variables. Categorical 
variables were compared with a general linear model with Sidak´s post hoc test or 
Cochrane Armitage trend test. 
Univariable associations were tested in univariable logistic and linear 
regression analyses. In linear regression, variables were entered into the multivariable 
models if p<0.10 in univariable analysis and removed by a stepwise procedure if 
p>0.10. Some variables were forced into the model if deemed either clinically or 
statistically relevant by an enter procedure. Collinearity tools were used in 
multivariable linear regression, with assessment of variance of inflation factor and 
tolerance. Model assumptions were tested by assuring that normality of the error 
distribution, linearity and homoscedasticity were not violated. The goodness of fit 
was expressed as the adjusted R2. Logistic regression analysis followed a similar 
procedure, but goodness of fit was tested by the Hosmer-Lemeshow test. 
In Study 2, survival analysis was performed using Cox proportional hazard 
regression and results are presented as hazard ratio (HR) with 95% confidence 
interval (CI). Proportional hazard assumptions were tested by Schoenfeld residuals 
for each independent continuous variable and by visual examinations of log-log plots. 
Nested models were compared using Akaike`s information criterion (AIC), 
which is based on the gold-standard likelihood ratio test but penalizes the addition of 




compared with the likelihood ratio test. The continuous net reclassification 
improvement (NRI) and Harrell C statistics were calculated to evaluate the 
discriminatory power between models with and without AT/ET ratio. Kaplan-Meier 
curves with log rank statistics visualized the unadjusted rate of event free-survival 
between high and low AT/ET ratio. Receiver operating characteristic curves were 
plotted to calculate the optimal cut-off to discriminate between high and low risk 
individuals with regards to AT/ET ratio. Non-linear relations between AT/ET ratio 
and the outcome variables were visualized in adjusted generalized additive models 
(GAM) with restricted cubic splines.  
 Intra- and inter-observer reliabilities were reported as intraclass correlation 
coefficient with 95% CI in Study 1. Intra-observer reliability of EF1 was calculated 
by reanalyzing 18 randomly selected participants analyzed twice by the same reader 
(EE) three months after initial reading. Inter-observer reliability was calculated by 
comparing baseline EF1 measurements between two readers (EE and SS) in 18 




10. Summary of results  
10.1 Study 1: Impact of arterio-ventricular interaction on 
first-phase ejection fraction in aortic stenosis. 
The aim of this study was to identify covariates of EF1 across the spectrum of AS 
severity. A total of 114 patients (48% women) with AS and LV EF≥50% were 
studied. In the study population, 38 patients had mild, 44 moderate and 32 severe AS, 
respectively. Median age was 73 years (age range 31-94 years), while the 
prevalence’s of hypertension were 89.5%, diabetes 11.4% and hypercholesterolemia 
46.5%, respectively. Patients with severe AS had significantly higher LV mass index 
and RWT (p<0.05). Measures of end-systolic function such as global longitudinal 
strain, EF and SVi did not differ between groups (p>0.05). Indices of peak LV 
systolic function, including AT, strain rate, and EF1 all progressively declined from 
mild to severe AS (all p<0.05). All measures of peak systolic function were 
significantly correlated with each other (Figure 9).   
Intra-observer and inter-observer agreement of EF1 measurements were good, 
with intraclass correlation coefficient 0.94 (95% CI [0.85-0.98]) and 0.88 (95% CI 
[0.67-0.95]), respectively (Figure 10). When analyzing the covariates of EF1 in 
univariable linear regression, EF1 was significantly associated with strain rate (β -
0.50), PP/SVi (β -0.29), peak aortic jet velocity (β -0.41), AT/ET ratio (β -0.38), 
filling pressure (β -0.27), LV mass index (β -0.24), in which higher values of all 
variables lowered EF1(all p<0.05). The correlation between EF and EF1 did not reach 
statistical significance (β 0.18, p=0.059). In multivariable linear regression analysis, 
the association between EF1 and strain rate, peak jet velocity and PP/SVi remained 
significant ( R2=0.40, p<0.001), while the association between EF1 and other 








Figure 9. Correlation plot showing the bivariate correlations 
between measures of peak systolic function.  
 
In a separate analysis, EF1 was analyzed as a dichotomous variable ( ≥25% or 
<25%). This cut-off was based on a previous study which found that a cut-off of 
<25% was associated with worse prognosis in patients with moderate and severe 
AS.49 In logistic regression analysis, EF1 shared the same covariates as EF1 in a 
continuous scale. Diastolic dysfunction was highly associated with EF1 <25% in 
univariable analysis (OR 4.36, 95% CI [1.74-10.90], p=0.002), but this association 





Figure 10. Bland Altman plots showing the variation between repeated 
measures of first-phase ejection fraction for intra-observer (A) and 
inter-observer (B) analyses. 
 
10.2 Study 2: Higher acceleration ejection time ratio 
predicts impaired outcome in non-severe aortic valve 
stenosis. 
The aim of this study was to assess the association between higher AT/ET ratio and 
outcome during follow-up in non-severe AS participating in the SEAS study. The 
total study population included 1530 patients (38% women) with a mean age of 67 
years and mean peak aortic jet velocity of 3.02 m/s. Patients were grouped into 
quartiles of AT/ET ratio at baseline, with the 1st quartile as the reference group. There 
was a significant trend of increasing AS severity by all conventional 
echocardiographic measures with increasing AT/ET ratio quartile (all p<0.05). The 
4th quartile had significantly lower LV EF, stress-corrected midwall shortening and 
higher prevalence of low SVi (all p<0.05).  
The covariates of AT/ET ratio were investigated in linear regression. In 
univariable analysis, higher AT/ET ratio correlated with lower values of stress-
corrected midwall shortening, LV EF, systolic blood pressure and presence of low 
SVi, and with higher LV mass, aortic jet velocity, heart rate and RWT, with male sex 




higher AT/ET ratio remained significantly correlated with higher peak aortic jet 
velocity and LV mass, and with lower LV EF, stress-corrected midwall shortening, 
and systolic blood pressure, and with presence of low SVi (multiple R2=0.124, all 
P<0.05) (Figure 11).  
 
Figure 11. Directed acyclic graph showing the complexity between 
correlates and confounders of higher AT/ET ratio. The grey boxes 
indicate the confounders which are adjusted for in multivariable 
analysis, blue boxes indicate variables which may influence outcome 
but is not associated directly with increased AT/ET ratio Pink boxes 
indicate variables which may or may not be associated with outcome, 
but their association with AT/ET ratio are explained through other 





In the total study population, the 4th quartile had a 2-fold higher HR of major CV 
events (P<0.001), a 2.5-fold higher HR of CV death and HF hospitalizations 
(P=0.005) and 2-fold higher HR for all-cause mortality (P=0.011) compared to the 1st 
quartile. All models were adjusted for covariates of AT/ET ratio identified in 
multivariable linear regression. Additionally, age and sex were forced into the models 
for adjustment. GAM curves showed an increasing rate of events for higher values of 
AT/ET ratio but also a lower partial hazard for lower values of AT/ET ratio (Figure 
12). 
 
Figure 12. GAM plots showing the partial hazard per value of AT/ET 
ratio in the total study population for major CV events (A), combined 
CV death and hospitalization for HF (B) and all-cause mortality (C). All 
plots are adjusted for peak aortic jet velocity, ejection fraction, left 















































Among the 1530 patients in Study 2, 28.3% (n=433) were found to have PLGAS. 
Restricting analysis only to include patients with PLGAS, the optimal cut-off for 
predicting CV death and HF hospitalizations was an AT/ET ratio >0.32. Adding 
AT/ET ratio >0.32 to a Cox regression model assessing CV death and HF 
hospitalizations, fitted with the same covariates as mentioned above, yielded a better 
model-fit by a lower AIC and a significant loglikelihood-ratio test (Figure 13). Model 
discrimination was assessed by Harrell C-statistics, which yielded slightly higher 
concordance-value for the model including AT/ET ratio >0.32 (0.758 – 0.768). 
Additionally, AT/ET ratio >0.32 improved reclassification of patients at risk for CV 
death and HF hospitalizations (NRI improvement > 0, NRI=0.446 (95% CI 0.161-
0.731) in the PLGAS group (Figure 13). 
 
Figure 13. Bar-plot showing the effect of adding AT/ET >0.32 ratio to a 
nested Cox regression model assessing CV death and HF 
hospitalizations among patients with PLGAS. The y-axis shows the 
overall chi-square distribution for the likelihood ratio test compared to 
an intercept model. The x-axis shows the fitted model and the model 





10.3 Study 3: Impact of obesity on persistent left 
ventricular hypertrophy after AVR for aortic stenosis 
The aim Study 3 was to assess the effect of preoperative obesity on presence of LV 
hypertrophy following AVR in severe AS patients. A total of 399 patients were 
included, mean age was 64 years and 64% were male. The participants were grouped 
according to BMI groups as either normal weight (BMI<25.0 kg m2), overweight 
(BMI 25.0-29.9 kg m2) or obese (BMI ≥30 kg/m2). Preoperatively, 163 patients were 
normal weight, 154 were overweight 85 were considered obese. Age, blood pressure, 
heart rate and serum creatinine were similar across BMI groups (all ANOVA 
p>0.05). In contrast, the prevalence of hypertension was significantly higher among 
obese patients (77% in normal weight, 84% in overweight and  89% in obesity, 
ANOVA p=0.043). Additionally, serum HDL cholesterol level was lower and serum 
triglyceride level higher in the obese group (ANOVA p <0.001). Obese patients were 
also less likely to be smokers (26% in normal weight,  21% in overweight and 11% in 
obesity, ANOVA p=0.038). Patients with obesity had higher LV mass and higher 
prevalence of LV hypertrophy both pre-and postoperatively (p<0.05) (Figure 14). 
Obese subjects also and lower prevalence of normal LV geometry compared to 
normal weighted subjects (p<0.001). Post-AVR, the prevalence of hypertrophy 
decreased in all groups, but eccentric LV hypertrophy was significantly higher in 
obese subjects (p=0.006). The prevalence of concentric LV hypertrophy was 
numerically higher in obese patients post-AVR but did not reach statistical 
significance (p=0.057) (Figure 15). Mean LV mass reduction post-AVR was similar 
in all groups. We observed a 11% reduction in LV mass among obese patients, a 10% 
reduction among overweight patients and a 10% among those with normal weight 
(p=0.945). Peak aortic jet velocity and mean transaortic pressure gradient across the 
prosthetic valve did not differ between groups (ANOVA p=0.565 and p=0.281, 
respectively). The prevalence of patient-prosthesis mismatch was also similar across 







Figure 14. Prevalence of LV hypertrophy preoperatively and 
postoperatively (A) and LV mass index preoperatively (B) and 
postoperatively (C).  
In univariable logistic regression analyses, persistent LV hypertrophy post-AVR was 
significantly associated with presence of obesity, lower midwall shortening and 
higher systolic blood pressure (all p <0.05). In multivariable logistic regression 
analysis, persistent LV hypertrophy remained associated with obesity (OR 3.75, 95% 
CI [2.04 – 6.91], p <0.001), lower pre-AVR midwall shortening  (OR 0.90, 95% CI 
[0.83 – 0.97], p=0.008) and higher pre-AVR systolic blood pressure (OR 1.02, 95% 
CI [1.01 – 1.03], p=0.003). Factors which could influence LV mass regression such 
as age, sex, patient-prosthesis mismatch, post-AVR mean transaortic gradient or 
duration of days from AVR to follow-up echocardiography were not associated with 
persistent LV hypertrophy in univariable analyses (all p>0.05), and therefore not 
included in the multivariable model. However, if these variables were forced into the 
multivariable model, the results remained unchanged. Higher BMI pre-AVR was 





Figure 15. Prevalence of different types of   geometry pre- 
















Optimal risk stratification and therapeutic decision making in AS require early 
detection of LV dysfunction, accurate grading of AS severity and an integrated 
assessment of CV risk factors for proper management and referral for timely 
intervention. The current PhD project studied peak systolic LV function, LV ejection 
dynamics and obesity in this context. In Study 1, our aim was to investigate if an 
impairment in EF1 could be detected in patients with preserved EF, and as such be 
regarded as a marker of early systolic dysfunction. In Study 2, we assessed whether 
higher AT/ET ratio could identify high-risk subjects among those with non-severe 
AS, thus providing additional insight in grading of AS severity independent of 
conventional measures. In Study 3, our aim was to investigate whether obesity could 
negatively influence lack of improvement in postoperative LV mass regression. The 
studies included in this thesis have added to current knowledge in several aspects. 
First, we demonstrate that EF1, a marker of peak systolic function, progressively 
declines from mild to severe AS and is closely related to myocardial contractility and 
arterial stiffness. Secondly, higher AT/ET ratio was independently associated with an 
increased risk of CV death and HF hospitalizations in non-severe AS and in patients 
with PLGAS. Lastly, we demonstrate that obesity is associated with persistent LV 
hypertrophy after valvular replacement, a factor known to influence post-AVR 
morbidity and mortality in these patients.   
11.1 EF1 in AS 
In AS EF may remain preserved until late in the disease progression. It should be 
noted that the occurrence of EF<50% in asymptomatic AS patients is rare, with a 
prevalence of only 0.4%.25 Indeed, approximately one third of patients with AS and 
preserved EF have significant evidence of LV systolic impairment when assessed by 
other methods.26 Importantly, recent studies have called into question the tradional 
50% cut-off proposed by the guidelines. Studies in severe AS have pointed out that 
those with EF between 50-59% have increased mortality compared to those with EF 




cause mortality was 55%, clearly contrasting the threshold of <50% for valvular 
intervention.91 Further, gender-specific cut-off values for normal LV EF values (52% 
in men and 54% in women) are promoted in the general recommendations for 
echocardiographic chamber quantification.72 Although these studies show that EF 
may inherit prognostic value, the current threshold value seems incorrect and may be 
improved. In this regard, EF1 has emerged as a novel marker of myocardial function 
that represents the early phase of EF measured at the time of peak aortic jet velocity, 
reflecting peak systolic function.46 A previous study has demonstrated the feasibility 
of EF1 measurements in AS, proposing a cut-off <25% as a predictor of poor 
prognosis, assessed from combined AVR, HF and all-cause mortality.49 Importantly, 
EF1 was a better predictor of outcome than LV myocardial long-axis function 
measured by global longitudinal strain, which has been shown to be a better predictor 
of outcome than LV EF in both severe and moderate AS.38,39 The rational of 
measuring EF1 early in systole as opposed to EF at end-systole, is that at peak 
myocardial contraction occurs predominantly in the first part of systole. As 
demonstrated by our results the most important correlate of EF1 was strain rate, a 
marker closely related to myocardial contractility. Even though strain rate may not 
directly measure myocardial contraction per se, a close relationship between strain 
rate and load independent markers of contractility have been demonstrated in 
experimental studies in animals.92,93 EF1 was also closely related to AT, as expected, 
since it has been demonstrated that strain rate and peak aortic jet velocity are almost 
simultaneous events during the cardiac cycle.94 These events coincide with peak 
myocardial wall stress which occur in early systole to fascilitate LV relaxation.95 EF1 
was more related to all measures of peak systolic function such as peak systolic 
annular velosity (S`), AT and strain rate compared to end-systolic markers such as 
EF, global longitudinal strain and SV. Taken together this suggest that EF1 should be 
regarded as a marker of peak systolic function in AS. This is of importance as events 
in early systole may be less load dependent, and thus more sensitive to contractile 
changes in the myocardium. It has been demonstrated in healthy subjects that peak 
systolic indices, such as strain rate and peak S`, are considerably more affected by 




hand, are measures of the total systolic workload performed by the LV during 
ejection. This may not represent peak systolic function since maximal load is reached 
at end-systole.          
 Weideman et al. showed in a porcine model that global longitudinal strain was 
more related to SV and EF, while strain rate was more related to invasive measures of 
contractility.97 In the same study, the authors showed that strain rate remained 
constant during an increase in heart rate, suggesting that it is relatively independent of 
heart rate variations.97 Similarly, we found no correlation between heart rate and EF1 
or strain rate, while SV and ET where were negatively associated with higher heart 
rate. In cases of high heart rate, these findings might be explained by the Bowditch 
effect or force-frequency relation.98 This implies that a faster stimulation may 
increases the force of contraction, which may maintain EF1 but decrease SV due to a 
decreased ejection duration and reduced venous return.    
 Strain rate has been shown to be affected by pre-and afterload,99 but to a 
considerably lesser degree than global longitudinal strain.43 Thus, the same is to be 
expected of EF1. In a study by Dahle et al. strain rate was significantly associated 
with changes of the time of maximum rate of LV pressure rise (dP/dt max) during 
isovolumetric contraction time.43 dP/dt max is considered a reasonable marker of 
contractility largely independent of afterload, although effected by preload by length 
dependent activation of myocardial fibers. With reduced contractility, a diminished 
rate of dP/dt max results in a prolongation of isovolumic contraction time and the pre-
ejection period.100 One would expect that reduced force generating capabilities in the 
isovolumetric phase may continue in early systole, prolonging AT and reducing EF1. 
Some of the unexplained variance in EF1 from our study could therefore be explained 
by the systolic timing events occuring prior to ejection.  
In our study, EF1 was not significantly correlated with overall EF in 
univariable analysis. Even though they both primarily represent cavity deformation 
and endocardial displacement during systole, EF1 seem to decline at an earlier stage 
than overall EF. This suggest that EF1 in early systole may differ from overall EF. It 




preserve overall EF despite reduced contractility.29 In a mathematical model, EF was 
shown to be unaffected by a reduction in longitudinal shortening by compensatory 
changes in circumferential strain or wall thickness.30 In the same study, Stokke et al. 
demonstrated that higher wall thickness and smaller LV chamber volumes may 
maintain EF >50% despite significantly reduced longitudinal and circumferential 
shortening.30 In line with this, other have also shown that circumferential strain 
contributes twice as much to EF compared to longitudinal strain.101 This may explain 
the clinical finding that some AS patients with low flow low gradient display 
pronounced concentric remodeling with small cavity size and impaired longitudinal 
function by peak S`, despite preserved EF.102 In line with this, we found that both 
peak S` and EF1 were lower in patients with severe compared to mild AS, despite 
preserved EF. Patients with a low EF1 had visually less displacement of the mitral 
annulus in early systole, explaining the correlation between a higher EF1 and higher 
peak S’. In contrast, we were unable to demonstrate a significant difference between 
global longitudinal strain across groups of AS severity, although there was a trend 
towards lower strain in patients with severe AS. In larger studies, lower global 
longitudinal strain has been reported in asymptomatic severe AS.103 Thus, our finding 
should be interpreted with caution and in the context of the existing body of 
literature. A reduction in longitudinal shortening prior to a reduction in 
circumferential shortening may be observed in AS because the subendocardial fibers 
of the LV, which are mainly oriented in the longitudinal direction, are more sensitive 
to ischemia. This may occur due to the increasing mismatch between subendocardial 
blood flow and oxygen demand as a results of increasing wall thickness and wall 
stress.104 Subsequently, fibrotic changes may first appear in the subendocardium and 
affect longitudinal shortening at an earlier stage of the disease.104 Events in early 
systole may therefore be more related to longitudinal rate of shortening, while end-
systolic events and EF may be more related to circumferential shortening in the 
midmyocardium and LV geometric remodeling. 
In two retrospective studies, EF1 was the most powerful predictor of combined 
AVR and all-cause mortality independently of global longitudinal strain.49,105 Taken 




systolic dysfunction, but the results need to be validated in prospective studies in the 
future.  
The association between EF1 and arterial function 
In Study 1, an important covariate of EF1 was PP/SVi, a measure of arterial stiffness, 
which has documented prognostic value in AS patients.106 Experimental studies have 
suggested that arterial stiffness could lead to reduced coronary flow and 
subendocardial fibrosis even in the absence of coronary artery disease.107 
Furthermore, arterial wave reflections have been associated with greater extracellular 
mass in patients with severe AS.108 In a magnetic resonance study by Bing et al. 
lower EF1 was significantly associated with more fibrosis detected by late 
gadolinium enhancement and higher indexed extracellular volume, representing focal 
replacement fibrosis and diffuse interstitial fibrosis, respectively.105 In their study, the 
main determinant of a low EF1 following AVR was infarct-related, non-reversible 
replacement fibrosis.105  
Similar to crude measures of arterial stiffness, backward traveling reflection 
waves arrive earlier in patients with higher central PP compared to those with lower 
central PP.109 In patients with arterial stiffness backward wave reflections may arrive 
in mid-to late systole rather than in diastole, further boosting central systolic blood 
pressure, increasing the myocardial oxygen consumption and lowering the ischemic 
threshold of the myocardium.110 A loss of diastolic pressure may further contribute to 
myocardial oxygen mismatch due to reduced coronary perfusion. It is therefore 
possible that the observed association between PP/SVi and EF1 might be mediated 
through early wave reflection induced ischemia which facilitates development of 
fibrosis when persisting over time.108 
However, since PP/SVi is derived from a Windkessel model it does not 
explicitly account for wave propagation and reflections.87 In our study, the 
association between EF1 and PP/SVi was primarily driven by a higher central PP. In 
the population based Strong Heart Study of 3,520 individuals, noninvasively 
determined central PP was a better predictor of vascular hypertrophy, atherosclerosis, 
and CV events than brachial blood pressure.111 For this reason we estimated the 




central PP compared to brachial PP. Several large studies in non-AS patients have 
documented the importance of increased PP as a risk factor for CV events.112,113 
Central PP has been thought to be mainly determined by stiffness of the aorta, which 
is amplified by age-related arterial stiffening.114 In hypertensive patients increased 
aortic stiffness, measured as aortic characteristics impedance, was the major 
determinant of higher PP.115 Because most of the central pressure rise is achieved 
during early systole, attributable to the forward pressure wave, aortic impedance and 
not wave reflections may influence peak wall stress and EF1 to a larger degree.108 
Since the first shoulder of the forward pressure wave coincide with peak aortic flow, 
the correlation between EF1 and PP/SVi could be mediated through the interaction 
between these two phenomena. However, the determinants of the forward pressure 
wave and central PP are not only influenced by arterial stiffness and aortic stiffness, 
but also by time-dependent LV ejection and SV.116,117   
In a recent study by Li et al., investigating the hemodynamic effects of age-
related increases in central PP among women, the authors measured time-dependent 
LV ejection volumes at the peak of the first shoulder of the forward pressure wave, 
equivalent to EF1, and LV volume at the peak of the second shoulder, compromising 
the sum of the forward and backward reflecting pressure waves. They found that a 
substantial component of the increase in central PP with age was due to an increase in 
augmentation pressure. The increase in augmentation pressure was best explained by 
the ratio of the LV ejection volume at the time of the second pressure wave to the 
aortic jet velocity at the first shoulder.117 This would be equivalent of a change in the 
ejection pattern similar to what is observed for EF1 in our study, with a lower ejected 
volume at EF1 in early systole and a greater proportion of ejected volume occurring 
later in systole, after the time of EF1. The authors propose that this could be 
explained by a reduction in EF1, which could sustain ejection to maintain overall EF 
and SV in cases with afterload excess through a reverse of the shortening deactivation 
phenomenon.46,117 The independent association between EF1 and PP/SVi in our study 
could therefore be mediated through reverse causality, where a lower EF1 would 




study and the study by Li et al. were cross-sectional and observational by nature, 
these studies are merely hypothesis generating.  
An association between EF1, arterial stiffness and ischemia could arise by the 
fact that myocardial wall stress has been shown to be a time-dependent 
phenomenon.95 Peak oxygen consumption is thought to relate most to peak 
myocardial wall stress which occur in early systole.118,119 This may correspond to the 
time of EF1, especially when AT is significantly prolonged. Peak wall stress is also 
more dependent on the impedance of the aorta and systemic vasculature than wave 
reflections.120 Since myocardial wall stress is dependent both on pressure, wall 
thickness and LV cavity size, as expressed by the law of Laplace, a less dynamic 
reduction of LV cavity size in early systole, or a lower EF1, will fail to reduce wall 
stress relative to pressure. This may further contribute to increased myocardial 
oxygen demand independent of wave reflections. Arterial stiffness in itself 
contributes to higher end-systolic wall stress, which increases LV remodeling, 
fibrosis, and impairs LV relaxation.110 A lower EF1 was in our study was 
significantly correlated with higher end-systolic wall stress, but when adjusting for 
PP/SVi this association was attenuated. This suggests that increased wall stress may 
be associated with lower EF1 downstream from the deleterious effects of increased 
arterial stiffness. Interestingly, increased arterial stiffness or reduced systemic arterial 
compliance have been associated with increased mortality both in hypertension and in 
patients with AS.87,106 One may speculate that EF1 might yield prognostic 
information in AS patients with concomitant arterial stiffness.  
EF1, global LV load and diastolic dysfunction 
In AS, hypertension and arterial stiffness are highly prevalent, especially in elderly 
subjects.121 Zva estimates the overall LV afterload caused by the combined valvular 
obstruction and arterial load.122,123 Increased Zva predicts impaired outcome in 
several studies involving AS.122,123 A high global LV load increases maladaptive LV 
remodeling and  has been associated with a low flow state.124 Similar to our findings, 
the study by Bing et al. found that a lower EF1 was significantly associated with 
higher Zva.105 Taken together, EF1 does show some afterload dependency. With a 




indexed extracellular volume and infarct-related late gadolinium enhancement only 
explained 25 % of the variance in EF1. In our study, strain rate was the major 
determinant of EF1 and our model in total predicted considerably more of the 
variance in EF1 (40%). This suggest that a low EF1 is not only caused by an afterload 
mismatch, but also reflects an impairment in intrinsic myocardial systolic 
contractility. This may explain why some patients with mild and moderate AS also 
had lower values of EF1. Known coronary artery disease was an exclusion criterion 
by design in our study. However, since coronary angiography was not conducted as a 
part of the study protocol and concomitant coronary artery disease is common in AS 
patients, we cannot exclude the possibility that subclinical coronary artery disease 
could contribute to reduced EF1 in mild and moderate AS.  
Gu et al. have documented that EF1 may be impaired in hypertensive patients 
with diastolic dysfunction.46 We corroborate these findings by demonstrating a linear 
relationship between higher filling pressure, estimated by the E/e’ ratio, and lower 
EF1. When we analyzed EF1 as a dichotomous variable with a previous proposed 
cut-off of <25%, there was a univariable association between diastolic dysfunction 
and lower EF1. However, this association was attenuated when we adjusted for strain 
rate and peak aortic jet velocity. This may partly be explained by the fact that only 25 
patients in Study 1 had low EF1. It may be difficult to retain significant associations 
in multivariable adjustments when the numbers are low.  
The association between EF1 and diastolic function could occur as a 
consequence of impaired shortening deactivation. In the normal heart, shortening 
deactivation refers to the reduced capacity of activated myocytes to further develop 
force after shortening. Shortening deactivation increases relaxation after onset of 
contraction and allows for early filling of the LV in diastole. Only sustained force 
development may allow for continued fiber shortening. Increased tension during 
systole may therefore prolong ejection but slow shortening velocity.125 With an 
increase in late systolic load, sustained force development may preserve overall EF, 
but at the expense of impaired diastolic relaxation.126 In AS, ejection duration usually 
increases with AS severity. In our data, higher ET was significantly associated with 




longitudinal strain remained unchanged by a longer ET. A lower EF1 and events in 
early systole could therefore be closely related to end diastolic events. In our study, 
there was a significant relationship between higher left atrial volume index and lower 
EF1, which persisted after adjustment for aortic jet velocity, arterial stiffness, global 
longitudinal strain, age, LV mass and gender, but not when adjusting for strain rate.  
11.2 Ejection dynamcis in AS 
The natural history and poor prognosis of severe AS have been well documented. 
However, moderate AS may also inherit poor prognosis.20 Patients with moderate AS 
usually present with many CV risk factors, and have significantly increased mortality 
compared to the general population.127 Most recently, in a large study of 122,809 
male (mean age 61 ± 17 years) and 118,494 female patients (mean age 62 ± 19 years) 
from Australia, Strange et al. reported a 5-year mortality of 56% in untreated 
moderate AS.22 In a Veterans Affairs cohort, 63 deaths were observed among 104 
individuals with moderate AS during a mean follow-up period of 1.8 years.128 
Coexistence of moderate AS and LV dysfunction is not uncommon and heralds poor 
outcome and high risk of clinical events.129 In a French population including patients 
with moderate AS and EF ≥50%, mortality rates were 13%, 28%, and 47% at 1, 3, 
and 6 years, respectively.127 Similar results were shown in patients with moderate AS 
and EF ≥50% in a study by Zhu et al., which demonstrated that impaired global 
longitudinal strain was associated with worse survival outcomes in both those who 
underwent AVR and in those who received conservative treatment.39  
Recent evidence suggests that a decline in EF may start before the AS becomes 
severe, with the decline accelerating after the AVA reaches 1.2 cm. 90 Taken together, 
this underlines the importance of detecting early LV dysfunction, and demonstrates 
that the prognosis in some patients with moderate AS is poor, despite an EF above 
50%.  
This provokes the idea that some AS patients might benefit from AVR at an 
earlier stage than currently recommended by the guidelines.16,17 Kang et al. showed 




deemed outside the guideline recommendations for valvular intervention, those who 
received early AVR had significantly lower CV mortality compared to those who 
received conservative care.23 Moreover, in patients with normal flow and low 
transvalvular pressure gradient, a phenotype classified as moderate AS by the 
European guidelines, AVR significantly improved survival compared to conservative 
treatment.130 Accordingly, it might be time to reconsider its indication in selected 
patients with moderate AS.  
Recent studies suggest that AT/ET ratio may be an angle independent marker 
that correlates with AS severity. In smaller studies, higher AT/ET ratio predicts 
mortality in patients with moderate-severe AS and in patients with low-gradient 
severe AS.55,56 LV ejection dynamics may therefore improve detection of high-risk 
individuals among patients with discordantly graded AS or moderate AS with 
subclinical systolic dysfunction.  
It is well known from early studies that a prolongation of the ET occurs with 
increasing AS severity.131 In more recent times, two different studies reported that AT 
increases in parallel with AS severity,132,133 which is consistent with the well-
recognized physical finding of a late peaking murmur in severe AS. Bermejo et al. 
who studied Doppler spectrograms in 15 patients with AS and 10 control subjects, 
suggested that a slow end-systolic opening of the aortic valve was more often 
observed in patients with AS than in controls.52 This may be visualized by a rounded 
contour of the systolic aortic flow waveform by Doppler with the peak moving 
towards mid-systole in severe AS, compared to a more triangular shape in less severe 
AS. The current guidelines on native AS state that the shape of the aortic flow 
waveform may be helpful when assessing AS severity.16 However, the AT/ET ratio 
quantifies this relationship, making it considerably more useful in clinical practice. 
So far, the AT/ET ratio has been incorporated in the echocardiographic evaluation of 
prosthetic aortic valve function, but not in the assessment of native valve AS.134 The 
clinical application of the AT/ET ratio was first demonstrated by Ben Zekry et al., in 
their study an AT> 100 milliseconds and an AT/ET ratio >0.37 was predictive of 
prosthetic valve obstruction.53 In a study of 108 patients with native mostly severe 




to discriminate between symptomatic and asymptomatic patients.135 The same 
optimal AT/ET cut-off of >0.35 was also able to reasonably differentiate severe AS 
from mild or moderate AS (sensitivity 59%, specificity 86%) in a small AS 
population.136 The association of higher AT/ET ratio with increased mortality in 
native severe AS was reported by Ringle Griguer et al.55 In their study of 456 
patients, higher AT/ET ratio was associated with symptoms and an AT/ET ratio 
>0.36 predicted increased mortality. In contrast to the population in paper 2, their 
study included patients with high co-morbidity, including diabetes, atrial fibrillation 
and coronary artery disease. Thus, our study extends their findings into a large cohort 
of AS patients without diabetes and overt CV disease and presumably non-severe AS. 
The finding of a lower prognostic threshold value for AT/ET ratio in our study, 
compared to previous studies, probably reflects that our study population had less 
severe AS, as AT/ET ratio increases in parallel with AS severity. Interestingly, the 
optimal prognostic threshold value of AT/ET ratio >0.32 identified in our cohort, 
corresponds to the recommended cut-off value to distinguish between mild and 
moderate prosthetic valve obstruction.134 Further, the threshold of an AT/ET ratio 
>0.36 proposed by Ringle Griguer et al. is rather similar to the recommended 
threshold value of >0.37 used to discriminate between moderate and severe prosthetic 
valve obstruction.134 Taking a closer look at the GAM plots from Study 2, it is 
apparent that not only higher AT/ET ratio is associated with an increased risk, but 
also lower values seems to be associated with a lower rate of all endpoints 
investigated. In light of previous work, it may seem that an AT/ET ratio <0.32 is 
highly suggestive of milder AS severity, while an AT/ET ratio >0.36 may be used to 
identify high-risk subjects among those with severe AS.   
 
ET is not only increased in AS, but also increases in relation with higher age, 
hypertension, arterial stiffness and diastolic dysfunction.125,137,138 Increased ET 
(≥ 320 ms) by impedance cardiography was shown to be a reasonable screening tool 
for diastolic dysfunction with a sensitivity of 90.2% and positive predictive value of 
76.6% among patients with hypertension.139 Weber et al. observed a prolongation of 




investigating LV adaptations during ageing in healthy subjects, there was an increase 
in ET with higher age. In this study age and diastolic E/A ratio by Doppler were the 
independent determinants of increased ET indexed for heart rate.140 In animal studies 
of senescence the duration of contraction and relaxation is prolonged.141,142 An 
increase in afterload during active contraction may prolong the duration of systole 
and slow relaxation.143 Considering that the first phase of diastole is dependent on 
active relaxation, the duration of diastole depends not only on heart rate but also to 
some extent on the duration of systole. Sustained contraction must imply a relative 
abundance of calcium. Accumulation of calcium at the onset of diastole may impair 
LV diastolic relaxation and early diastolic filling. This may maintain SV, but at the 
expense of diastolic filling.144,145 An increase in ET may therefore be an adaptive 
mechanism in the early phases of AS. Since ET varies inversely with heart rate and 
directly with SV,146 estimation of transvalvular flow rate (SV/ET) rather than SVi 
may be more appropriate to identify low flow in AS. Transvalvular flow rate has been 
shown to predict outcome in several AS populations.147-149 This has the advantage of 
representing the systolic flow across the valve, which could be reduced in the setting 
of a prolonged systolic ejection period, even with a normal SV. This underlines the 
importance of evaluating timing of systolic events in AS.  
LV ET is sensitive to inotropic alterations and preload. It can be observed that 
there is a delayed onset of ejection and that ET shortens when systolic failure 
occurs.150,151 Similarly, in patients with severe AS who develop LV systolic 
dysfunction, the ET tends to be less prolonged compared to patients with AS and 
preserved LV systolic function.152 This suggests that both shortening as well as a 
prolongation of the ET is associated with an impaired prognosis, which may explain 
the u-shaped relationship between mortality and ET observed in a large study of 
patients with coronary artery disease.138 In our cohort of presumably non-severe AS, 
ET was significantly lower in those with higher AT/ET. Higher AT/ET ratio was also 
significantly associated with lower stress-corrected midwall shortening, suggesting 
that both lower ET and a higher AT/ET ratio may imply early systolic dysfunction. 
This may partly explain why those with higher AT/ET ratio had higher rate of CV 




Deterioration of LV systolic function is characterized by a decreased rate of 
LV pressure rise (dP/dt) during the isovolumetric contraction period.100 When preload 
reserve is exhausted and progressive systolic dysfunction occurs, SV declines and 
cardiac output becomes heart-rate dependent. This may not only shorten the ET, but 
may increase the pre-ejection period.153 The pre-ejection period is defined as the time 
interval from the Q-wave of the electrocardiogram until the onset of ejection. This is 
equal to the electromechanical delay plus the isovolumic contraction time. Therefore, 
changes in the pre-ejection period are largely dependent on isovolumic contraction 
time, which increases in HF. Weissler and colleagues demonstrated in 1968 that 
patients with HF had significantly shorter ET and longer pre-ejection periods 
compared to normal individuals at any given heart rate.153 More recent studies have 
confirmed that the pre-ejection period/ET may be a useful index of overall LV 
performance that correlates well with overall EF, global longitudinal strain and dP/dt 
max.100 Even though we did not measure the pre-ejection period but rather the AT, 
one would expect that a diminished rate of LV pressure rise during the isovolumetric 
contraction period could continue in the early phases of systole and prolong the AT. 
A prolongation of the AT is likely to occur as a direct effect of valve obstruction, but 
may also reflect systolic dysfunction with reduced ability of the LV to generate force. 
An early peak of AT is found in healthy individuals, with the peak occurring before 
mid-systole as opposed to patients with severe AS. Higher AT may therefore be 
considered as a combined marker of reduced contractility and valve obstruction. This 
might be of particular relevance in low-flow states, where AT and the AT/ET ratio 
may be increased in non-severe AS because of the lack of LV ejection force to open 
the valve despite only mild or moderate calcification. From a hemodynamic 
standpoint, an early peak of AT may reduce energy dissipation compared to a late 
peak, as demonstrated in vitro by Hatoum et al.154 Ejection dynamics may in itself 
control some of the energy efficiency of the aortic valve. When acceleration is 
slower, more energy dissipation occurs. This may to some degree determine the 
formation and strength of vortices in the aorta, which suggest that a delayed AT in 
AS is not compensatory.154,155 In some patients with discordantly graded AS, and 




due to the pressure recovery phenomenon. In these patients one would expect that AT 
would be longer, since a late peak is associated with higher energy dissipation. 
In Study 2, we observed that the AT/ET ratio was directly correlated with 
higher AS severity. Across quartiles there was a larger difference in AT between 
groups compared to the difference in ET which was lower in the higher quartiles. On 
the other hand, in Study 1, we found no difference in ET across mild to severe AS. In 
Study 1, we also observed that AT in itself was significantly increased from mild to 
moderate and severe AS, confirming previous observations.133 This suggests that 
since both AT and ET is prolonged in compensated AS, the observation of a higher 
AT/ET ratio with increasing AS severity is explained by a longer AT relative to the 
ET.  
An important limitation of both AT and ET is that they are both heart rate 
dependent. A faster heart rate implies shorter AT, regardless of AS severity. The 
AT/ET ratio may to a certain degree reduce this limitation by dividing the AT by the 
ET, canceling out the effect of heart rate. In Study 2, there was a low but significant 
association between higher heart rate and lower AT/ET ratio in univariable analysis. 
When we adjusted for possible confounders this association became non-significant. 
However, since heart rate was within normal limits in our study, the AT/ET ratio 
should be interpreted with caution in patients with tachycardia. 
In linear regression in Study 2, higher AT/ET ratio was correlated with several 
risk factors that have been shown to predict outcome both in severe and non-severe 
AS. These included higher LV mass, systolic blood pressure and markers of LV 
myocardial dysfunction. Importantly, higher LV mass has been shown be an 
important predictor of outcome in the SEAS population.156 The link between higher 
AT/ET ratio and increased LV mass is likely to be mediated through increased 
midwall fibrosis in the non-contractile component of the myocardium, which 
contributes to LV dysfunction when LV hypertrophy progresses.157,158 Usually, 
development of LV hypertrophy may in the early stages of AS adapt to the increased 
afterload to maintain wall stress and cardiac output, but largely reflects co-
morbidities like hypertension, arterial stiffness or obesity rather than the valvular 




mass relative to wall stress may occur, a condition called inappropriately high LV 
mass. In a study by Cioffi et al., inappropriately high LV mass shared many of the 
same covariates as higher AT/ET ratio, including lower stress-corrected midwall 
shortening.161 Interestingly, the coexistence of hypertension did not influence either 
the prevalence nor magnitude of inappropriate LV mass in a cross-sectional study 
from the SEAS population, possibly reflecting the high prevalence of hypertension in 
this study cohort.162 In those with inappropriately high LV mass, indices of afterload 
and contractility were actually lower while RWT was higher, despite similar degrees 
of AS severity.162 This makes an argument that structural changes may explain 
reduced contractility in these patients. This offer an explanation to why higher AT/ET 
ratio was associated with higher LV mass independent of AS severity.  
In accordance with previous results,163 higher AT/ET ratio was associated with 
lower systolic blood pressure in Study 2. The occurrence of either systemic 
hypertension or reduced arterial compliance have in a combined experimental and 
clinical study shown to reduce the transaortic mean pressure gradient and peak aortic 
jet velocity independent of flow status.164 With regards to AT/ET ratio, higher 
afterload and wave reflections during the systolic phase could induce compensatory 
lengthening of the ET, which would lower the AT/ET ratio.125,165 This may also result 
in systolic flow deceleration and induce shortening of AT, as observed in a study 
measuring AT during exercise and rest in healthy subjects.166 A study in healthy 
young and elderly subjects showed that there exists an inverse relation between 
higher carotid-femoral pulse-wave velocity and ET, which persist through all age-
categories independent of heart rate.167 However, in their study, the contribution of 
ET explained only 2-5% of the variance in pulse-wave velocity. Additionally, mean 
systolic blood pressure in all age-categories were within the normotensive range. This 
suggests that these results cannot be extrapolated to our elderly hypertensive AS 
patients. Further studies are therefore needed to elucidate the mechanisms behind 
lower systolic blood pressure and higher AT/ET ratio.  
Kadem et al. showed that hypertension may reduce the transaortic mean 
pressure gradient and peak aortic jet velocity, contributing to discordant AS 




through a decrease in LV contractility, SV and transvalvular flow.169 However, a 
lower AT/ET ratio due to afterload driven decrease in SV is unlikely, as low flow was 
associated with higher AT/ET ratio independent of systolic blood pressure in our 
cohort. Kadem et al. offer a different explanation by speculating that in AS the aortic 
root may expand as aortic pressure increase, resulting in an increase in AVA 
irrespective of flow rate.168,170 A slight increase in AVA due to aortic root expansion 
might offer less resistance to the aortic flow, easing acceleration, lowering AT and 
thus the AT/ET ratio. In our study, there is a possibility that study site physicians 
recognized those with higher AT/ET ratio as more high-risk individuals. These 
patients tended to have more severe AS by conventional measurements, higher 
prevalence of low flow and higher burden of moderate-severe valve calcification. As 
such these patients might have been treated more aggressively with antihypertensive 
treatment. To some degree this was accounted for, since we adjusted for AS severity 
in multivariable analysis. Despite this, we cannot exclude that hypertension treatment 
bias may partly explain the association between higher systolic blood pressure and 
lower AT/ET ratio, since we did not have detailed information on in-study changes in 
hypertension management.  
 As recommended by the guidelines AS severity, and probably also AT/ET 
ratio, should be reassessed when systolic blood pressure is normalized.16 However, 
antihypertensive treatment may often fail to normalize arterial compliance or blood 
pressure in elderly subjects despite appropriate treatment. An important finding from 
our study is therefore that higher AT/ET ratio seems to predict increased risk of CV 
events independent of systolic blood pressure or hypertension. Consequently, AS 
patients with hypertension and high AT/ET ratio may be a particular high-risk group.  
The role of increased AT/ET ratio in patients with PLGAS  
Therapeutic decision making remains difficult in discordantly graded AS like 
PLGAS. The 2014 American Heart Association/ American College of Cardiology 
(AHA/ACC) valvular disease guidelines acknowledges that there exists a high 
prevalence (5% to 25%) of low-gradient severe AS in patients with preserved LV EF. 
This low-gradient entity may raise uncertainty regarding the actual severity of the AS 




of particular importance if the patient presents with dyspnea, which alternatively may 
originate from comorbidities such as chronic obstructive pulmonary disease, obesity, 
hypertension or coronary artery disease, and not from the AS itself. At present, the 
current European guidelines regard patients with normal flow-low gradient as 
moderate AS.16 Studies focusing on the natural progression and risk in patients with 
paradoxical low flow-low gradient or normal flow-low gradient (together comprising 
the entity of PLGAS) have shown conflicting results. One study suggested that during 
follow-up, most patients with PLGAS may develop adverse concentric remodeling 
and low-flow before the development severe AS.171 In the SEAS study, PLGAS 
patients showed the same rate of outcome as patients with moderate AS.172 On the 
contrary, some propose that PLGAS should be considered a more advanced disease 
stage, more akin to HF with preserved EF.173,174 Even though the debate on how to 
manage these patients is still ongoing, a meta-analysis from Dayan et al. concluded 
that PLGAS was associated with increased risk of mortality compared to other 
subtypes of AS.27 Improved identification of high-risk patients among those with 
PLGAS is therefore of utter importance. However, conflicting results have been 
noted, with some studies reporting no benefit of AVR among patients with PLGAS. 
These studies suggested that those with normal flow low gradient should be regarded 
as low risk patients.102,175,176 On the contrary, recent data from the PARTNER 2 trial, 
consisting of 3511 patients with AS, found that outcomes after AVR were equally 
good in patients with PLGAS as in those with high-gradient severe AS.177 In the same 
study, similar rates of the primary outcome was observed among PLGAS and high-
gradient severe AS.177 However, the PARTNER 2 trial included symptomatic AS 
patients, and a direct comparison between our asymptomatic population should be 
done with caution. In line with previous literature, patients with PLGAS in our cohort 
included more women with smaller LV cavities, more concentric LV remodeling, 
lower LV myocardial function and higher prevalence of low flow compared to the 
total study population. Of note, an AT/ET ratio>0.32 improved identification of high-
risk patients among those with PLGAS, independent of these prognostic factors. Our 
results expand previous observations in symptomatic PLGAS patients with 




In our cohort of PLGAS patients, both those with normal flow and low flow were 
included. Since low flow is a strong predictor of worse outcome in AS,178,179 an 
important finding from our results is that an AT/ET ratio >0.32 predicted increased 
risk of CV death and HF hospitalizations independent of low flow. It is well known 
that discrepancies between AVA and mean transaortic pressure gradient may arise 
because of low flow.180 Hence, in the presence of low flow there may not be 
sufficient power to generate a pressure difference that exceeds the threshold of severe 
AS despite a low effective orifice area. Estimation of AT/ET ratio may improve 
identification of high-risk subjects since it increases with low flow. Consideration of 
systolic ET in AS may be of importance in patients with discordant AS grading, as a 
study by Kadem et al. found that a modification of ET could translate into a 
difference in mean transvalvular gradient of 15 mmHg independent of SV.181 
Other possible mechanisms for discordant grading may include measurement 
errors, small body size, but also inherent inconsistencies in the guideline criteria. In a 
large study by Minners et al., the current threshold of an AVA of 1.0cm2 as a cut-off 
to define severe AS, corresponded more precisely to a mean transaortic pressure 
gradient of 30-35 mmHg rather than the currently used threshold of 40 mmHg as a 
definition of severe AS.182 Compared to measurement of transvalvular gradients, 
AT/ET ratio may be less angle-dependent, as the absolute values of peak and mean 
pressure gradients may be lowered by incorrect angulation, but the timing of events 
(AT and ET) may remain the same.  
 
Other approaches to classify high-risk PLGAS patients may include evaluation 
of serum biomarkers,183 low-dose dobutamine echocardiography,184 and aortic valve 
calcium score by multidetector computed tomography.185 In our study population 
computed tomography was not included as a part of the study protocol. Several 
studies have validated a simpler approach by assessing aortic valve calcification by 
echocardiography, which was used in the present study.13,186 As demonstrated by 
Cramariuc et al., moderate-severe calcification by echocardiography was associated 
with higher CV event rate in both sexes, and with higher all-cause mortality in 




presence of moderate-severe calcification by echocardiography in univariable 
analysis. In multivariable analysis, this relationship became non-significant, probably 
due to high collinearity between peak aortic jet velocity and calcium score. 
Nonetheless, an independent correlation between higher AT/ET ratio and higher 
calcium score by computed tomography has been reported by others.163 Since calcium 
score is a flow-independent marker of AS severity, a correlation between higher 
AT/ET ratio and higher calcium burden may contribute to the prognostic value of 
higher AT/ET ratio.  
11.3 Obesity and persistent LV hypertrophy after AVR 
During progression of AS, an increase in LV mass is due both to cellular hypertrophy 
and development of myocardial fibrosis. While cellular hypertrophy and diffuse 
fibrosis may regress after valvular replacement, midwall replacement fibrosis on the 
other hand seems irreversible, and may hinder cardiac remodeling after AVR.188,189 
Myocardial replacement fibrosis in patients with severe AS has been proposed as a 
cause of persistent LV diastolic dysfunction and symptoms after AVR, and is closely 
linked to increased mortality during postoperative follow-up.104,190,191 Lack of 
normalization of LV mass after AVR is likely to involve presence of replacement 
fibrosis, but also residual diffuse interstitial fibrosis which may take longer time to 
regress than cellular hypertrophy. Residual fibrosis also predicts outcomes during 
progression of AS.192,193 A proportion of those with persistent LV hypertrophy after 
AVR in our study are likely to have irreversible fibrosis to some extent. This is 
supported by the finding that higher amount of fibrous tissue in myocardial biopsies 
at the time of AVR is associated with residual LV hypertrophy also after AVR.194 In 
line with this, sequential biopsy findings from Krayenbuehl et al. proposed that an 
early regression of LV mass after AVR is predominately driven by a reduction of 
cellular hypertrophy, whereas a decrease in myocardial fibrosis (albeit incomplete) 
may be observed 6-7 years later.195 This is consistent with more contemporary studies 
focusing solely on regression of LV mass by echocardiography or magnetic 




long as up to 5-10 years, but with the majority of the reduction occurring within the 
first six months up to a year following AVR.60,196-200 In our study, the post-AVR 
echocardiogram was taken after a median of 196 days(mean 208 days). This may 
explain why the duration of days from AVR to follow-up echocardiography in our 
study did not seem to influence the extent of LV mass regression. Most of the 
regression of LV mass is therefore likely to have occurred in the early phases of the 
postoperative period. Similarly, in a study in AS patients with severe LV hypertrophy 
treated with transcatheter AVR, 50% of the first year LV mass regression occurred 
within the first 30 days.58  
The importance of LV hypertrophy regression for long-term prognosis after 
AVR for AS have been well documented.60,201 In a recent study by Gonzales et al. 
severe LV hypertrophy at one year after transcatheter AVR was associated with a 
16% increased risk of all-cause death, 26% increased risk of CV death and a 45% 
increase in the risk of rehospitalizations during a median of 3 years follow-up.202 
Greater LV mass regression at one year was independently associated with lower 
rates of death and hospitalization up to five years after transcatheter AVR.200 Taken 
together, AVR tend to promote regression of LV mass and improve LV function.203 
However, this might not always occur, and many patients fail to experience LV mass 
regression despite appropriately sized aortic valve prosthesis.200 
As the correlation between LV mass and myocardial fibrosis is only modest, it 
may be that patients with persistent LV hypertrophy have more myocardial fibrosis, 
which may explain the discrepancies between preprocedural hypertrophy and 
outcomes.194 Furthermore, only a modest correlation between the degree of AS 
severity and LV mass exists.204,205 The remodeling process of the LV during 
progression of AS is determined by numerous factors which may not resolve 
following AVR. The presence of concomitant hypertension, obesity, metabolic 
syndrome and arterial stiffness have been shown to influence LV mass and geometry 
in patients independent of AS severity.160,206,207 Understanding of the factors 
contributing to persistent LV hypertrophy after AVR is of importance. Knowledge of 
these factors could help to identify when it may be optimal to intervene, or provide 




study is that obese patients had significantly higher prevalence of persistent LV 
hypertrophy during the first 6 months after surgical AVR. Obese patients had 
considerably higher LV mass before AVR, but a similar reduction in LV mass after 
AVR compared to normal weight and overweight. This suggests that the effect of 
valve replacement on the LV was equal across BMI classes. A more adverse 
remodeling during progression of AS, thus seems to translate to more residual 
hypertrophy also after AVR. This finding is supported by studies in obese subjects 
without AS, where there is positive correlation between severity of obesity and higher 
LV mass. Prior to our study, documentation regarding the effect obesity on LV 
hypertrophy after surgery for AS was scarce. However, two smaller studies primarily 
focusing on circulatory levels of micro-ribonucleic acids had noted a negative impact 
of higher preoperative BMI on less LV mass regression following AVR.208,209  
 
 Obesity may induce or maintain LV hypertrophy in AS patients through a 
number of hemodynamic and non-hemodynamic mechanisms.210 From a 
hemodynamic perspective, obesity may impose a residual overload on the LV caused 
by a hyperdynamic circulation and increased blood volume.211 This may explain the 
higher prevalence of eccentric hypertrophy observed in obese patients after AVR in 
our study, as LV overload usually induce eccentric hypertrophy. At baseline in the 
SEAS study, eccentric LV hypertrophy was more common in obese patients than in 
their leaner counterparts. However, during progression of AS the LV geometry 
changed considerably, and at the last study visit concentric LV hypertrophy was the 
predominant type of abnormal LV geometry irrespective of BMI class. This suggests 
that after AVR the effect of obesity on LV remodeling reverts to that observed in the 
milder stages of AS. Afterload may also be elevated in obese subjects after AVR due 
to large artery stiffening,211 which may negatively influence regression of myocardial 
fibrosis.108  
With respect to metabolic effects, obesity may induce cardiac steatosis through 
accumulation of epicardial and pericardial fat, which has been shown to increase 
myocardial fibrosis and lead to more pathological remodeling during progression of 




subsequently leading to reduced LV function.210 Results from magnetic resonance 
imaging suggest a pathophysiological role of myocardial steatosis in the development 
of systolic dysfunction in AS, independent of obesity.213 Marfella et al., showed that 
in severe AS patients with metabolic syndrome, systolic function decreased as 
myocardial steatosis increased in myocardial biopsies.214 In patients without obesity 
this steatosis seems to reverse after AVR, facilitating improvement in LV strain 
measured by magnetic resonance tagging.213 In the presence of obesity, alterations in 
cardiac fatty acid metabolism may favor lipid accumulation within the myocardium 
also after AVR. Because increased myocardial triglyceride content has been shown to 
increase LV mass and reduce LV function,44,215 one may speculate if the observed 
relationship between persistent LV hypertrophy and obesity could occur as an 
epiphenomenon since triglyceride levels significantly increased across BMI classes in 
our cohort. Elevated levels of serum triglycerides are a component of atherogenic 
dyslipidemia, common in those with metabolic syndrome. The metabolic syndrome is 
associated with a cluster of metabolic risk factors beyond obesity, such as 
hypertension, impaired glucose regulation and dyslipidemia which could influence 
both pre-and postoperative LV mass. When our study was published, there had been 
less focus on the effect metabolic syndrome on LV mass regression following AVR. 
Later, Guzzetti et al. showed that those with metabolic syndrome had less LV mass 
regression and higher prevalence of persistent LV hypertrophy after AVR.216 
However, in a re-analysis done after publication, forcing any component of the 
metabolic syndrome into the multivariable model in Study 3, such as serum-
triglycerides or high-density lipoproteins, did not change the association between 
obesity and persistent LV hypertrophy. This suggests a crude effect of obesity on 
increased LV mass beyond dyslipidemia.  
Progressively lower LV myocardial function, assessed by midwall shortening, 
was found with increasing BMI class. This trend was evident both before and after 
AVR. This effect was also found throughout the SEAS study.159 Previous studies on 
midwall mechanics in obese patients indicate that lower midwall shortening is related 
to abnormalities in LV geometry, particularly concentric LV hypertrophy.217,218 In 




hypertrophy, despite EF being >60% in the majority of patients. This finding is in 
accordance with other authors who also found that worse systolic function, measured 
by peak S´, was an independent predictor of persistent LV hypertrophy after AVR for 
AS.194 
Other potential mechanisms that may link obesity to LV hypertrophy are 
insulin resistance, activation of the renin-angiotensin system and sympathetic nervous 
system, low-grade inflammation and a high prevalence of comorbidities such as 
hypertension and obstructive sleep apnea. Even though we could not account for all 
of these potential confounders in our dataset, the relationship between persistent LV 
hypertrophy and obesity was independent of higher systolic blood pressure. This is of 
importance as higher systolic blood pressure may impose a residual load on the LV 
and hamper LV mass regression.63,219 Cramariuc et al. identified hypertension, 
together with AS severity and male sex, as the main baseline determinants of LV 
hypertrophy in the SEAS population.220 Our findings shows that the detrimental 
effect of higher systolic blood pressure also continues after AVR. Other factors of 
residual load include patient-prosthesis mismatch, which has been identified as an 
important factor associated with lack of LV hypertrophy regression after surgical 
AVR.221,222 In our cohort, the prevalence of patient-prosthesis mismatch did not differ 
between groups, and there was no association between persistent LV hypertrophy and 
severe patient-prosthesis mismatch.  
 Our results have implications for the timing of AVR in obese patients, as it 
may be suggested to intervene at an earlier timepoint as these patients have adverse 
remodeling which may not adequately regress after AVR. However, our study 
demonstrate that LV mass reduction was comparable in obese and non-obese 
subjects. Thus, weight reduction in these patients may be beneficial to normalize LV 
mass after AVR, while earlier AVR will not. Even a modest weight loss is almost 
invariably associated with a reduction in LV mass.217,223 This effect also appears to be 
stronger than the decrease in LV mass associated with a concomitant reduction of 
blood pressure.217 Voluntary weight loss induced by bariatric surgery or life-style 
modifications may therefore produce favorable changes in cardiac structure and 





The results reported in this thesis should be considered in the light of some 
limitations. The main statistical limitations in Study 1 are the cross-sectional study 
design and small sample size. This precludes evaluation of causal effects, and some 
of the observed correlations might be bi-directional. It should be emphasized that 
results from cross-sectional studies are mainly hypothesis generating. Prospective 
studies are needed to confirm the impact of increased arterial stiffness and myocardial 
contractility with EF1. Further, the small sample size may also increase the risk of 
type-II statistical errors. This limited the possibility of investigating how EF1 might 
have been distributed across different flow gradient patterns. However, the sample 
size of 120 patients was calculated beforehand in order to have 90% power with 
statistical level of 0.05 to find a 20% difference in myocardial function between AS 
severity groups, including an anticipated dropout rate of 10%.  
In general, a single center observational design reduce external validity as the 
analysis may be subject to referral bias. However, since patients were recruited 
prospectively this strengthens that our results may be generalizable to other AS 
patients. Furthermore, we cannot exclude that coronary artery disease may have been 
present in some patients, since computed tomography angiography was not a part of 
the study.  
The SEAS study population, investigated in Study 2 and 3, was a multinational 
population of patients with initially asymptomatic mild to moderate AS without 
known CV diseases, diabetes mellitus, kidney disease, HF or other significant heart 
valve diseases. Our results are therefore not directly comparable to other AS groups 
expressing any of these comorbidities. Nevertheless, this population allowed us to 
investigate the impact of increased AT/ET ratio in AS, and the association between 
concomitant obesity and persistent LV hypertrophy, without many confounding 
factors. The SEAS study was a randomized clinical trial designed to assess the impact 
of lipid-lowering treatment on AS progression. The main limitation in Study 2 and 3 
is therefore the post-hoc study design which does not conform to the randomization 




discovered herein might occur by coincidence increase as the SEAS study was not 
originally planned for these studies. A post-hoc study design may also increase the 
risk of type-II statistical errors, due to the fact that no a priori power-analyses were 
done with these research questions born in mind. However, our results are clearly in 
line with previous results and generates hypotheses that should be formally 
investigated in future prospective studies.  
11.4.1 Methodological considerations  
General considerations 
In all three papers, magnetic resonance imaging assessment of fibrosis, computed 
tomography assessment of calcium-score, dobutamine stress-testing or venous blood 
samples with measurement of cardiac biomarkers such as B-natriuretic peptides were 
not available due to resource constraints. We cannot exclude that assessment of any 
of these modalities could have provided additional information regarding underlying 
disease mechanisms beyond the tools investigated in the present thesis. However, 
echocardiography remains the main tool for management of AS patients.  
Accuracy of cine-magnetic resonance imaging may allow for identification of 
alterations in cardiac structure and function that may be missed using two-
dimensional echocardiography. Three-dimensional echocardiography is available and 
may also measure cardiac volumes and LV mass directly. Three-dimensional 
echocardiography have several advantages compared to two-dimensional 
echocardiography. It does not require image plane positioning to avoid apical 
foreshortening and eliminates the need of geometrical assumptions. This provides a 
more precise representation of chamber quantification. Accuracy of three-
dimensional LV volumes and EF have demonstrated superiority compared to two-
dimensional echocardiography. Improvement of LV mass estimation due to better 
endocardial and epicardial visualization may explain why three-dimensional 
echocardiography is more closely related to the of gold-standard by magnetic 
resonance imaging. However, three-dimensional echocardiography is more dependent 
on image quality, which is a prerequisite for accurate volume and LV mass 




present with poor acoustic windows. The application of magnetic resonance imaging 
is limited by increased time to acquire and analyze images, and its accessibility is 
restricted compared to echocardiography. 
The Devereux`s necropsy method for LV mass calculation was used in all 
studies. This assumes a fixed geometric shape, which may be a source of error, 
especially with major distortions of LV geometry. The calculation of LV mass is 
based on the modeling of the LV as a prolate ellipsoid, and any error in linear 
measurements can results in significant inaccuracies because the measurements are 
cubed in the formula. This may be of particular importance, especially in Study 3, 
where the main variable of interest was LV mass and LV hypertrophy. The impact of 
these potential technical pitfalls may be partly limited by the large number of 
observations, which reduce the error. Despite the limitations noted, two-dimensional 
echocardiographic assessment of LV mass is recommended in AS follow-up, and the 
majority of the existing prognostic data are from studies using two-dimensional 
detection of LV hypertrophy.  
Several methods have been proposed to normalize LV mass to body size. We 
chose to index LV mass to height2.7 as it gives the most accurate estimation of LV 
mass and the most sensitive cut-off for LV hypertrophy, particularly in obesity. 
Additionally, core laboratory readings were done in all studies, following the 
recommendations for utility of echocardiography in clinical studies. All clinical and 
demographic data were collected prior to echocardiography and all imaging analyses 
were done blinded, as recommended for clinical trials.   
Specific limitations  
Study 1  
In Paper 1, we measured strain rate by speckle tracking echocardiography as a 
surrogate of contractility. However, strain rate is load-dependent and not a perfect 
measure of contratility. The main methodological limitation in Paper 1 is therefore 
the lack of a load-independent marker of contractility. Ideally, EF1 should be 
compared against contractility indices derived from invasive pressure volum loops 
such as the slope of the linear preload recruitable stroke work, which is insenstive to 




Alternatively, comparing EF1 to the end-systolic pressure-volume relation or dP/dt 
max during different loading conditions would be a more appropriate assessment of 
EF1 as a marker of contractility. There are several advantages with speckle tracking 
derived strain rate compared to other methods such as Tissue Doppler Imaging. 
Speckle tracking allows for a faster post-processing because it is 
automatic/semiautomatic and is less angle dependent compared to Tissue Doppler 
Imaging. However, speckle tracking achieves significantly lower frame rate than 
Tissue Doppler imaging, which may cause an underestimations of peak strain and 
especially peak strain rate in subjects with high heart rate. This may to a certain 
degree have influenced strain rate in our population.   
Although intra- and inter observer reliability for measurements of EF1 was 
good, EF1 was measured by the two-dimensional bi-plane Simpson’s method. As 
previously stated this method is limited by geometrical assumptions and 
measurements made in a routine clinic may exhibit more variability. Automated 
three-dimensional analysis may provide a more reliable measurement of EF1 without 
geometrical assumptions, and would be the preferred method for future studies. 
However, the current commercially available software for three-dimensional 
echocardiography is limited by low temporal resolution and stitching artefacts. Low 
volume rates (10-30 volumes per second) implies that it may be difficult to identify 
the exact frame of EF1, as there may be large discrepancies between frames with 
three-dimensional echocardiography compared to high-frame rate two-dimensional 
images.   
Study 2  
In the SEAS study deformation analysis including strain and strain rate was not 
investigated, as this was not a part of the SEAS study protocol. Adding deformation 
analysis may have elucidated important confounders which could not be adjusted for 
in our cohort. In multivariable Cox regression analyses, we did not adjust for AVA 
which is recommended in the guidelines when assessing AS severity. The rational for 
this was that AVA was not significantly associated with higher AT/ET ratio in the 
multivariable models. However, if AVA was forced into the Cox regression models 




Since we excluded patients with EF<50%, our results should be interpreted 
with caution in AS patients with classical low flow low gradient. Even though we 
found a non-significant association between higher AT/ET ratio and heart rate in 
multivariable analyses, it’s likely that AT/ET ratio could be more affected in cases 
with higher heart rates. Similar to most measures of systolic function, measurement 
of AT/ET ratio seems dependent on loading conditions. Precautions must be 
considered for interpretation of AT/ET ratio in AS patients with coexistence of other 
valvular heart disease that alters LV hemodynamics.  
Study 3 
The selection of patients referred for AVR were done by local study personell, which 
may favour patients with certain features. The specific indications for surgery were 
not forwarded to the core laboratory, and thus information regarding development of 
sympomts were not collected in our database. However, the collection of data from 
several independent hospitals, analysed by the core laboratory, significantly reduces 
the risk of referal bias. In the SEAS study echocardiography protocol, only LV filling 
and atrial volumes were assesed, while no data on mitral annular plane velocites or 
tricuspid reguritation were included in this study that was performed in 2002-2008. 
This limited the evaluation of diastolic function. It is known that obesity is associated 
with worse LV diastolic function independent of LV mass and other risk factors.225 
Also, LV diastolic dysfunction may persist in AS patients even after transcatheter 
AVR, and is an independent predictor of outcomes.226 Lastly, BMI may be inferior to 
other measures of fatness like waist circumference or waist-to-hip ratio, which were 
not collected in the SEAS study. The rational of using BMI dependends on the 
assumptions that anthropometric measures correlates with more direct measures of 
adiposity such as excess fat mass, subcutanous fat or visceral fat which are more 
metabolic active. This may not always be the case and some studies support the 
notion of addition of waist circumference or waist-to-hip ratio when assessing 
BMI.227 However, other suggest that most of the variance in obesity-related 
anthropometrics is captured by BMI which makes an argument for the use of BMI in 




11.5 Clinical implications and future perspectives  
The present project demonstrates that EF1 is a marker of peak systolic function while 
ejection dynamics may improve identification of high-risk individuals among 
presumable non-severe AS patients, including PLGAS patients. Our results indicate 
that EF1 may be a promising marker of early systolic dysfunction that incorporates 
the effect of both arterial and ventricular function. Although retrospective studies 
suggest that EF1 may inherit predictive value, future prospective longitudinal studies 
are needed to confirm whether EF1 has true prognostic value in both AS patients and 
other heart disease cohorts. If these results are confirmed, EF1 may be an easy 
echocardiographic marker that could effortlessly be implemented in clinical practice.  
Higher AT/ET ratio seems to be a promising angle-independent marker of AS 
severity that could be especially useful in patients with discordant graded AS. In the 
same matter, future studies with addition of deformation analysis and computed 
tomography assessment of calcium score should assess the prognostic value of higher 
AT/ET ratio. The present project also demonstrates that obesity has a pronounced 
association with persistent LV hypertrophy and higher LV mass also after AVR for 
severe AS. Since higher BMI did not influence the magnitude of LV mass regression, 
interventions to induce weight-loss in a safe manner both pre-and postoperatively 





12. Conclusions  
The present thesis investigated several pre-specified aims and found the following 
answers related to the scientific questions asked:   
 
Study 1  
The purpose of Study 1 was to identify the covariates of EF1 in patients with mild, 
moderate and severe AS. Especially, the associations between EF1, myocardial 
contractility and arterial stiffness were of interest. This paper suggests that EF1 is a 
promising marker of peak systolic function that may detect early systolic dysfunction 
among AS patients before end-systolic markers. Our results show that lower strain 
rate as a surrogate of myocardial contractility and higher PP/SVi as a surrogate of 
arterial stiffness are important covariates of lower EF1. 
 
Study 2  
The purpose of Study 2 was to assess the impact of LV ejection dynamics measured 
as AT/ET ratio on CV outcome in patients with non-severe AS. The present study 
shows that higher AT/ET ratio may improve identification of high-risk subjects 
among patients with mild, moderate and inconsistently graded AS. In the subgroup of 
asymptomatic patients with PLGAS, an AT/ET > 0.32 improved identification of 
patients at high-risk for combined CV death and HF hospitalization. 
 
Study 3  
The purpose of Study 3 was to investigate the effect of preoperative obesity on 
persistent LV hypertrophy after AVR for severe AS. Our study show that obesity has 
a strong association with residual LV hypertrophy that is independent of known 
prognostic factors such as patient-prosthesis mismatch, higher systolic blood pressure 
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Aims First-phase ejection fraction (EF1), the EF at the time to peak aortic jet velocity, has been proposed as a novel
marker of peak systolic function in aortic stenosis (AS). This study aimed to explore the association of myocardial




Data from a prospective, cross-sectional study of 114 patients with mild, moderate, and severe AS with preserved
left ventricular EF (>50%) were analysed. EF1 was measured as the volume change from end-diastole to the time
that corresponded to peak aortic jet velocity. Myocardial contractility was assessed by strain rate measured by
speckle tracking echocardiography. Arterial stiffness was assessed by central pulse pressure/stroke volume index
ratio (PP/SVi). The total study population included 48% women, median age was 73 years, and mean peak aortic jet
velocity was 3.47 m/s. In univariable linear regression analyses, lower EF1 was associated with higher age, higher
peak aortic jet velocity, lower global EF, lower global longitudinal strain, lower strain rate, and higher PP/SVi. There
was no significant association between EF1 and heart rate or sex. In multivariable linear regression analysis, EF1
was associated with lower strain rate and higher PP/SVi, independent of AS severity. Replacing PP/SVi by valvular
impedance did not change the results.
...................................................................................................................................................................................................
Conclusion In patients with AS, reduced myocardial contractility and increased arterial load were associated with lower EF1 in-
dependent of the severity of valve stenosis.
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Introduction
Aortic stenosis (AS) is the most common cause of aortic valve re-
placement in developed countries.1,2 Once symptoms occur or there
is a reduction in left ventricular ejection fraction (LVEF) <50%, the
current guidelines recommend aortic valve intervention.3,4 The tran-
sition to symptoms partly reflects maladaptive compensatory mecha-
nisms,5 particularly characterized by myocardial fibrosis which may
not reverse following aortic valve replacement.6
Experimental research has suggested that when systolic function is
impaired in early systole an intrinsic mechanism may exist to preserve
LVEF, but at the expense of a slower and sustained contraction.7,8
However, in AS it is well known that LVEF may be preserved by com-
pensatory remodelling and hypertrophy,9 despite reduced myocar-
dial contractility.10 Recently, the first-phase EF (EF1), a measurement
of the LVEF at the time of peak aortic jet velocity, has emerged as a
novel marker of early LV systolic impairment both in hypertension
and AS patients.11,12 Early and accurate recognition of subclinical LV
systolic dysfunction offers the potential to optimize the timing of
intervention in AS. In patients with moderate or severe AS, lower
EF1 showed incremental prognostic value compared with LVEF and
global longitudinal strain.12 However, more information on the
underlying factors influencing EF1 is needed. In particular, the inter-
action between EF1 with myocardial contractility and increased
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arterial load needs further exploration. Increased arterial load is high-
ly prevalent in AS patients due to higher age, hypertension, and large
arterial stiffening. Previous studies have documented the association
of arterial stiffness with impaired myocardial function.13 This study
aimed at exploring the associations between myocardial contractility
and arterial load with EF1 in AS.
Methods
Study population
We prospectively recruited 120 patients with AS from the outpatient
clinic, Department of Heart Disease, Haukeland University Hospital,
Bergen, Norway, between October 2015 and December 2017. Patients
were considered eligible if they had at least mild AS defined as aortic valve
thickening and peak aortic jet velocity >2 m/s. Exclusion criteria were car-
diac arrhythmias, prior pacemaker implantation, other concomitant
valvular disease of more than moderate grade, known coronary artery
disease (myocardial infarction, coronary artery bypass grafting, or percu-
taneous coronary intervention), or previous cardiac surgery. Patients
with reduced LVEF (<50%) (n= 3) were excluded from the present ana-
lysis. The study was approved by the local Regional Committee for
Medical and Health Research Ethics, and was conducted in accordance
with the Declaration of Helsinki. All patients signed a written informed
consent prior to study examinations.
Cardiovascular risk factors
Following inclusion, all participants underwent a clinical examination at
the outpatient clinic. Before the echocardiographic examination, brachial
blood pressure (BP) was measured in triplicate with 1-minute intervals
after an initial 5 minute rest in the seated position using a regularly cali-
brated aneroid sphygmomanometer and appropriate cuff size.14 The
average of the last two measurements was taken as the clinic BP.
Hypertension was defined as use of antihypertensive medication, history
of hypertension, or clinical BP >_140/90 mmHg. Self-reported health was
recorded on a standardized questionnaire including information on car-
diovascular risk factors, medication, and known diseases and was quality
assured by study personnel.
Echocardiography
A standardized transthoracic echocardiogram was performed in all
patients using a Vivid E9 scanner (GE Vingmed Ultrasound, Horten,
Norway). Digital images were stored and analysed at the Bergen
Echocardiographic Core Laboratory using TomTec workstations
equipped with Image Arena 4.6 soft-ware (TomTec, Unterschleissheim,
Germany). Conventional measurements in all studies were first analysed
by the same reader (E.E.) and later proof-read by an experienced reader
(E.G.). Quantitative assessment of the LV and AS severity were per-
formed according to the joint European Association of Echocardiography
and American Society of Echocardiography recommendations.3,15 LV
mass was calculated using the Devereux formula, and indexed to body
height in the allometric power of 2.7 to obtain LV mass index.16 LV
hypertrophy was defined by the prognostically validated cut-off values of
LV mass index >49.2 g/m2.7 in men and LV mass index >46.7 g/m2.7 in
women.16 LVEF was calculated using the Simpson biplane method. Peak
aortic jet velocity was measured from different acoustic windows includ-
ing the use of a stand-alone probe, and the highest velocity was used for
tracing of the time-velocity integral. The effective aortic orifice area was
calculated by the continuity equation. Mild AS was defined as peak aortic
jet velocity of 2.0–2.9 m/s, moderate AS as peak aortic jet velocity of 3.0–
3.9 m/s, and severe AS as peak aortic jet velocity >_4.0 m/s.
Stroke volume (SV) was assessed by Doppler and indexed for body
surface area, as recommended by the guidelines.4 Central pulse pressure
(PP) was estimated using a validated formula: brachial PP  0.49þ age 
0.30þ 7.11.17,18 Arterial stiffness was estimated by the ratio from central
PP/SV index (PP/SVi).17 Global LV load was assessed from valvuloarterial
impedance (Zva), calculated as systolic BP þ mean aortic pressure gradi-
ent/SVi.19 Peak systolic annular velocities were measured by tissue
Doppler imaging at the medial and lateral annulus, and averaged to obtain
peak S0.
EF1 was measured by the biplane method of discs by measuring the
volume change from end-diastole to the time that corresponded to peak
aortic jet velocity by spectral Doppler. EF1 was thus derived by:
EF1 ¼ ðEDV  V1Þ
EDV
where EDV is the LV volume at end-diastole and V1 is the LV volume
at the time corresponding to peak aortic jet velocity in the cardiac cycle
(Figure 1).12 EF1 was measured manually at the exact frame of peak aortic
Figure 1 Measurement of first-phase ejection fraction, and its re-
lation with global ejection fraction, global longitudinal strain, and
strain rate.






















































jet velocity by taking into account the frame rate and time in milliseconds
from aortic valve opening to peak aortic jet velocity.
Two-dimensional speckle tracking echocardiography and EF1 analyses
were performed offline on a dedicated workstation equipped with
EchoPac BT 202 (GE Vingmed Ultrasound, Horten, Norway), using apical
two-, three-, and four-chamber views with frame rate optimized to 60–
90 frames/s (median 74 frames/s, mean 73 frames/s). The endocardial
border of the LV was traced, and the region of interest was adjusted at
the epicardial border per segment, as appropriate. After software proc-
essing, tracking quality was checked visually, and all segments were
adjusted manually if needed. The time of aortic valve closure was meas-
ured from a pulsed wave Doppler recording in the LV outflow tract, and
was defined as the end of systole. Drift compensation was used during
analysis, and smoothing parameters were kept at default. Global longitu-
dinal strain was calculated as the average peak negative longitudinal short-
ening from the 18 LV segments. Longitudinal strain rate values from the
18 LV segments were averaged to obtain peak systolic strain rate.
Diastolic function was defined in accordance with current guidelines,20
if at least three of the following parameters were present: reduced annular
e0 velocity by tissue Doppler (septal e0 < 7 cm/s or lateral e0 < 10 cm/s);
early transmitral E-wave/average mitral annular velocity ratio (E/e0) >14;
biplane left atrial volume index >34 mL/m2; tricuspid regurgitant jet vel-
ocity >2.8 m/s.
Statistical analyses
Statistical analyses were performed using IBM SPSS version 25.0 (IBM,
Armonk, NY, USA). The study population was divided into three groups:
mild, moderate, and severe AS. Findings are reported as mean ± standard
deviation for continuous variables and as percentages for categorical vari-
ables. Normal distribution was checked prior to analyses by Q–Q plots
and normality tests (Kolmogorov–Smirnov). Groups were compared by
analysis of variance (ANOVA) with Scheffe’s post-hoc test for continuous
variables and by general linear model with Sidak’s post-hoc test for cat-
egorical variables, respectively. Covariates of EF1 were identified in uni-
variable and multivariable linear regression analyses using an enter or
stepwise procedure. The core assumptions of normality of the error dis-
tribution, homoscedasticity, and linearity were tested and not violated.
Multicollinearity was assessed by the variance of inflation factor. Results
are presented as standardized b-coefficients and P values. Goodness of fit
is expressed as the adjusted R2. Independent covariates of EF1 <25%
were tested in univariable and multivariable binary logistics regression
analyses. Results are presented as odds ratio (OR) and 95% confidence
interval (CI). Goodness of fit was tested with Hosmer–Lemeshov’s test.
For intra- and interobserver variability, intraclass correlation coefficients
were calculated to assess agreement between EF1 measurements. Intra-
and interobserver variability of EF1 measurements were assessed in 18
randomly selected subjects by repeated analyses 3 months after initial
reading. A two-tailed P value <0.05 was considered statistically significant
in all analyses.
Results
A total of 120 patients (48% women) were recruited and median age
was 73 years (age range 31–94 years). Six patients were excluded,
three because of suboptimal echocardiographic images, and three
due to reduced LVEF (<50%), leaving 114 patients eligible for the in-
clusion in the present analysis. 16 patients (nine with severe AS and
seven with moderate AS) had mild symptoms. Among those with
symptomatic severe AS, six patients received aortic valve interven-
tion, one patient was offered aortic valve replacement but declined,
while two patients were considered not eligible for valve replace-
ment due to severe comorbidities including cancer. The prevalence
....................................................................................................................................................................................................................
Table 1 Clinical characteristics across patients with mild, moderate, and severe AS
Mild (n ¼ 38) Moderate (n ¼ 44) Severe (n ¼32) P (ANOVA)
Age (years) 72 ± 10 71 ± 12 76 ± 9 0.133
Sex (male) 45% 57% 47% 0.513
Systolic blood pressure (mmHg) 153 ± 25 146 ± 18 143 ± 15 0.063
Diastolic blood pressure (mmHg) 84 ± 11 83 ± 7 79 ± 9* 0.036
Heart rate (bpm) 66 ± 10 68 ± 9 71 ± 12 0.119
Body surface area (m2) 1.89 ± 0.19 1.91 ± 0.24 1.84 ±0.23 0.278
Weight (kg) 78 ± 14 78 ± 18 72 ± 16 0.159
Height (cm) 170 ± 10 171 ± 9 170 ± 9 0.803
Body mass index (kg/m2) 26.9 ± 4.1 26.6 ± 4.6 25.0 ± 3.8 0.066
Hypertension, n (%) 33 (90) 40 (91) 29 (88) 0.912
Diabetes, n (%) 5 (13) 6 (14) 2 (6) 0.563
Current smokers, n (%) 1 (3) 4 (9) 3 (9) 0.109
Symptoms, n (%) 0 (0) 7 (16) 9 (28)* 0.011
NYHA functional class, n (%)
2 0 (0) 6 (14) 8 (25)
3 0 (0) 1 (2) 1 (3)
Hypercholesterolaemia, n (%) 7 (18) 9 (20) 7 (22) 0.938
NYHA, New York Heart Association; bpm, beats per minute.
*P< 0.05 vs. mild AS.






























..of hypertension was 89.5%, diabetes 11.4%, hypercholesterolemia
46.5%, and diastolic dysfunction 25.4%. Clinical characteristics be-
tween groups of mild, moderate, and severe AS did not differ, except
for diastolic BP which was lower in patients with severe AS (Table 1).
Patients with severe AS had significantly higher LV mass index and
relative wall thickness (both P< 0.05). Global longitudinal strain,
LVEF, and SVi did not differ between groups (Table 2). Indices of peak
LV systolic function, including acceleration time, strain rate, and EF1
all progressively declined from mild to severe AS (all P< 0.05)
(Table 2 and Figure 2). Filling pressure (E/e0) increased in parallel with
the increasing AS severity grade (P < 0.05).
The intraclass correlation coefficient for EF1 was 0.94 (95% CI
0.85–0.98) for intra-observer variability and 0.88 (95% CI 0.67–0.95)
for interobserver variability, reflecting excellent reproducibility. In
univariable linear regression analyses in the total study population,
lower EF1 was associated with higher LV mass index, older age, and
end-systolic wall stress (Table 3). Lower EF1 was also associated with
lower global longitudinal strain, lower strain rate, and with higher
peak aortic jet velocity. Higher EF1 was associated with a higher peak
S0. In bivariate analyses, EF1 was negatively correlated with higher
Zva (r = -0.33, P< 0.001), PP/SVi (r = -0.29, P= 0.002), higher central
PP (r = -0.29, P= 0.002), higher brachial PP (r = -0.25, P= 0.009), and
with symptoms (r = -0.34, P< 0.001). No association between hyper-
tension and EF1 was detected (P= 0.123). In multivariable linear re-
gression, lower EF1 was associated with lower strain rate
independent of age, peak aortic jet velocity, LV mass index, diastolic
dysfunction, and LVEF (Table 3, Model 1). In Model 2, lower EF1 was
associated with higher PP/SVi independent of age, peak aortic jet vel-
ocity, LVEF, and global longitudinal strain (Table 3). Replacing PP/SVi
by Zva did not change the results. In Model 3, we included all
....................................................................................................................................................................................................................
Table 2 Echocardiographic characteristics across patients with mild, moderate, and severe AS
Mild (n¼38) Moderate (n¼ 44) Severe (n¼ 32) P (ANOVA)
Peak aortic jet velocity (m/s) 2.5 ± 0.3 3.5 ± 0.3* 4.6 ± 0.5** <0.001
Mean aortic gradient (mmHg) 13 ± 3.5 26 ± 4.1* 50 ± 13** <0.001
Aortic valve area (cm2) 1.83 ± 0.34 1.26 ± 0.32* 0.91 ± 0.21** <0.001
Zva (mmHg/mL/m2) 2.9 ± 0.8 3.3 ± 0.9 3.6 ± 0.8* 0.001
LV end-diastolic diameter (mm) 47 ± 6 47 ± 6 45 ± 6 0.246
LV end-systolic diameter (mm) 31 ± 5 31 ± 5 29 ± 5 0.116
Septal wall thickness (mm) 13 ± 2 13 ± 3 16 ± 3** <0.001
Posterior wall thickness (mm) 9 ± 1 10 ± 2 11 ± 2* 0.014
Relative wall thickness 0.41 ± 0.08 0.42 ± 0.09 0.48 ± 0.10** 0.003
LV hypertrophy (%) 34 39 56 0.151
LV mass (g) 195 ± 59 198 ± 65 235 ± 90 0.040
LV mass index (g/m2.7) 46.2 ± 11.9 45.6 ± 11.6 54.8 ± 16.0** 0.006
PP/SVi (mmHg/mL/m2) 1.19 ± 0.29 1.17 ± 0.34 1.20 ± 0.28 0.922
Meridional end-systolic stress (dyne/cm2) 179 ± 37 184 ± 42 192 ± 41 0.376
Systolic function
Global ejection fraction (%) 63 ± 4 62 ± 5 64 ± 5 0.216
Global longitudinal strain (%) -20.5 ± 2.0 -20.0 ± 2.3 -19.1 ± 3.2 0.061
Peak S0 (cm/s) 8.1 ± 1.6 7.8 ± 1.2 7.0 ± 1.2** 0.002
Stroke volume index (mL/m2) 55 ± 10 52 ± 10 55 ± 11 0.319
Global longitudinal strain rate (s-1) -1.05 ± 0.16 -1.03 ± 0.15 -0.94 ± 1.17* 0.017
Mechanical dispersion (ms) 44 ± 12 43 ± 17 57 ± 21** 0.001
First-phase ejection fraction (%) 31 ± 4 30 ± 4 27 ± 4** <0.001
Diastolic function
Filling pressure (E/e0) 11.1 ± 5.5 12.4 ± 5.2 13.9 ± 4.6* 0.010
Peak e0 (cm/s) 6.9 ± 1.6 6.9 ± 1.5 5.7 ± 1.2** <0.001
Tricuspid jet (m/s) 2.47 ± 0.47 2.59 ± 0.33 2.54 ± 0.38 0.460
Left atrial volume index (mL/m2) 33.5 ± 8.5 36.0 ± 12.3 38.9 ± 11.6 0.139
Diastolic dysfunction, n (%) 5 (11) 13 (30) 11 (36)* 0.036
Ejection dynamics
Acceleration time (ms) 78 ± 17 93 ± 18* 111 ± 15** <0.001
Ejection time (ms) 314 ± 31 313 ± 27 323 ± 36 0.353
Acceleration/ejection time ratio 0.25 ± 0.05 0.30 ± 0.05* 0.35 ± 0.05** <0.001
LV, left ventricular; ms; milliseconds; PP/SVi, pulse pressure/stroke volume index; Zva, valvuloarterial impedance.
*P< 0.05 vs. mild AS
**P< 0.05 vs. mild and moderate AS.































































































significant variables from the univariable analyses in a stepwise pro-
cedure. Lower strain rate, higher peak aortic jet velocity and higher
PP/SVi all remained as significant and independent covariates of EF1
(all P< 0.05) (Table 3). Higher acceleration time was also associated
with lower EF1 in univariable analysis (b = -0.46, P< 0.001). Due to a
strong collinearity between peak aortic jet velocity and acceleration
time, these two variables were not included in the same multivariable
model. However, replacing peak aortic jet velocity with acceleration
time in secondary models, did not change the results, and the as-
sociation between EF1 and acceleration time remained significant
in all multivariable models (data not shown). When restricting
analyses only to moderate and severe AS groups, the association
between PP/SVi and EF1 in multivariable stepwise regression be-
came stronger (b = -0.35, P< 0.001), the association between
peak velocity and EF1 slightly attenuated (b = -0.27, P= 0.006),
while the association between EF1 and strain rate remained
unchanged (b = -0.39, P< 0.001).
In univariable logistic regression analysis, EF1 <25% was associated
with higher mechanical dispersion (OR = 1.03, P= 0.022), but after
multivariable adjustment the association was attenuated (P> 0.05). In
multivariable logistic regression analysis, EF1 <25% shared the same
covariates as for EF1 in a continuous scale (Table 4).
Discussion
The detection of early myocardial dysfunction in AS may be challeng-
ing. After the development of symptoms, there is a sharp increase in
the risk of irreversible myocardial damage and mortality. Irreversible
myocardial damage is often referred to as midwall fibrosis on late
gadolinium enhanced cardiac magnetic resonance imaging, which is
common in AS and reduces the survival benefit of aortic valve
replacement.21 EF1, a measure of peak systolic LV function, has been
shown to predict outcome more precisely than the traditional
markers of end-systolic LV function like LVEF and global longitudinal
strain in patients with AS.12 The present study adds to previous
knowledge by demonstrating that EF1 progressively declined with
increasing AS severity, and that lower EF1 was associated with lower
global longitudinal strain rate and higher PP/SVi independent of AS
severity.
The association between EF1 and strain
rate
Cardiomyocyte contraction occurs predominantly in the first part of
systole and peaks approximately at the time of peak aortic jet vel-
ocity. It has been demonstrated that strain rate and peak aortic jet
velocity are almost simultaneous events in the cardiac cycle,22 and
their respective timing intervals in early systole corresponds well
with peak force development in individual cardiomyocytes.23 In line
with these findings, we observed a closer association between EF1
and peak strain rate than with global longitudinal strain and EF1 in the
present study.
Even though strain rate does not directly measure peak myocardial
contraction per se, the relationship between strain rate and contract-
ility has been shown in an experimental pig model.24 Weidemann
et al. demonstrated that while strain rate was related to contractility,
global longitudinal strain was more closely related to SV and LVEF.25
EF1 and strain rate are measures of peak systolic performance, and
are therefore less load dependent, and more closely related to con-
tractility, which is in line with our findings. In contrast, end-systolic
measures, such as LVEF and global longitudinal strain, are more asso-
ciated with maximal LV load which is reached in late systole. As dem-
onstrated by our results, EF1 showed a progressive reduction from
mild to severe AS while LVEF remained within the normal range
across all grades of AS severity. Similarly, EF1 was also closely related
to peak S0, a reliable marker of systolic function that has been closely
related to contractility.26
Peak systolic indices are also better markers of changes in inotrop-
ic alterations.26 Strain rate often remains constant during an increase
in heart rate, suggesting that it is relatively independent of heart rate
variations.25 Similarly, no correlation between heart rate and EF1 was
detected in this study.
Strain rate has been shown to be affected by both preload and
afterload, but to a lesser degree than end-systolic markers.27 In this
regard, it is inevitable that EF1 to a certain degree is load dependent
due to its close correlation with strain rate. This is reflected by our
findings, as EF1 remained associated with peak strain rate independ-
ent of both PP/SVi and AS severity, together representing the total
arterial- and valvular load on the LV. Thus, lower EF1 is not just a con-
sequence of afterload excess, but reflects impairment in intrinsic
myocardial systolic contractility. These results are in line with previ-
ous research demonstrating that in severe AS patients, the ratio be-
tween wall stress and LVEF is significantly reduced, indicating
reduced contractility.28 This highlights the fact that watchful waiting
for spontaneous symptoms in some patients with severe AS may lead
to irreversible damage in LV myocardium. As recommended by the
guidelines, valve replacement is recommended in patients with
asymptomatic very severe AS (peak jet velocity > 5.5 m/s).3,29 We
Figure 2 Distribution of first-phase ejection fraction (EF1) in sub-
groups of AS.











































hypothesize that EF1 could be particular useful in this setting as a sen-
sitive and prognostically validated tool to guide treatment decisions
in patients with asymptomatic severe AS and normal LVEF in the
future.
The association between EF1 and
arterial stiffness
In AS, increased LV load is caused by combined arterial and valvular
resistance. Increased arterial load in AS is commonly caused by
hypertension and/or increased arterial stiffness.19,30 Interestingly, in
this study higher PP/SVi, a surrogate of arterial stiffness, was identified
as an important covariate of EF1. In patients with arterial stiffness, the
reflected-wave reaches the proximal aorta in early systole, boosting
systolic BP and increasing myocardial oxygen demand.20 Early wave
reflections increase the pulsatile load in mid-systole, and may occur
at the time corresponding to EF1. This underlines the importance of
time-varying systolic load on LV function. The increased tension in
early systole might prolong contraction, preserving LVEF at the ex-
pense of an impaired early systolic function and diastolic relaxation.
We corroborate previous findings by demonstrating a significant uni-
variable relationship between EF1 and filling pressure.11
In our data, EF1 correlated better with the estimated central PP
than with brachial PP. This is in line with previous findings which
showed that central aortic PP was a better predictor of target organ
damage.31 Higher PP/SVi has also been demonstrated as an independ-
ent predictor of cardiovascular events and all-cause mortality in
hypertensive patients.32 Furthermore, one could speculate that the
arterio–ventricular coupling demonstrated in the current study,
could contribute to the observed impaired prognosis in AS patients
with reduced arterial compliance.18
Limitations
This study was small and performed in AS patients with acceptable
image quality, and assessment may be less feasible and reproducible
in patients with poor acoustic windows. In addition, cause–effect rela-
tions cannot be determined due to the cross-sectional study design.
PP/SVi is an echocardiographic surrogate of arterial stiffness. The re-
lationship between EF1 and a more direct and accurate measure of
arterial stiffness, such as the gold standard pulse wave velocity, should
be tested in larger outcome studies in the future.
EF1 was significantly associated with self-reported symptoms.
However, the true prevalence of symptoms in our study cohort may
have been underestimated since a treadmill exercise test was not
.................................... ..................................... ..................................... .....................................
....................................................................................................................................................................................................................
Table 3 Linear regression analyses of covariates of first-phase ejection fraction










Global longitudinal strain rate (s-1) -0.50 <0.001 -0.38 <0.001 -0.40 <0.001
PP/SVi (mmHg/mL/m2) -0.29 0.002 -0.27 0.003 -0.28 <0.001
Peak aortic jet velocity (m/s) -0.41 <0.001 -0.26 0.003 -0.36 <0.001 -0.33 <0.001
Age (years) -0.28 0.003 -0.20 0.021 -0.11 0.241 NS NS
Global ejection fraction (%) 0.18 0.059 0.13 0.106 0.15 0.059 NS NS
Left ventricular mass index (g/m2.7) -0.24 0.011 -0.02 0.833 NS NS
Diastolic dysfunction (yes/no) -0.29 0.002 -0.09 0.284 NS NS
Filling pressure (E/e0) -0.27 0.004 NS NS
Global longitudinal strain (%) -0.40 <0.001 -0.28 0.001 NS NS
Peak S0 (cm/s) 0.46 <0.001 NS NS
End-systolic wall stress (dyne/cm2) -0.26 0.005 NS NS
Acceleration time (ms) -0.46 <0.001 NS NS
Body mass index (kg/m2) 0.18 0.060 NS NS
Heart rate (bpm) -0.07 0.469 NS NS
Hypertension (yes/no) -0.15 0.123 NS NS
Mechanical dispersion (ms) -0.15 0.127 NS NS
Systolic blood pressure (mmHg) -0.15 0.077 NS NS
Zva (mmHg/mL/m2) -0.33 <0.001 NS NS
Relative wall thickness ratio -0.12 0.188 NS NS
Posterior wall thickness (mm) -0.20 0.033 NS NS
Septal wall thickness (mm) -0.21 0.027 NS NS
Acceleration/ejection time ratio -0.38 <0.001 NS NS
Model 1, multiple R2 0.37, P< 0.001; Model 2, multiple R2 0.37, P< 0.001; Model 3, multiple R2 0.40, P< 0.001. Model 1: multivariable model of the association between EF1 and
global longitudinal strain rate. Model 2: multivariable model of the association between EF1,global longitudinal strain and PP/SVi. Model 3: multivariable stepwise regression
model, including all significant variables from univariable analyses.
ms, milliseconds; NS, not significant; bmp, beats per minute; PP/SVi, pulse pressure/stroke volume index; Zva, valvulo-arterial impedance.































































performed to assess revealed symptoms. In our study, there was
some overlap in EF1 across mild, moderate and severe AS , which
might limit its application in patients with less severe AS. This needs
to be studied in larger studies with less severe AS. Coronary artery
disease is common in AS patients. Although known coronary artery
disease was an exclusion criterion by design, we cannot exclude that
asymptomatic coronary artery disease may have been present in
some participants with reduced EF1. In severe AS, higher serum B-
type natriuretic peptide has been independently associated with
lower global longitudinal strain.33 However, B-type natriuretic pep-
tide was not measured in the present study, and the relation to EF1
could therefore not be assessed. Lastly, both EF1 and strain rate val-
ues were derived from the B-mode frame rate. This could lead to
inaccuracies in the measurement of EF1 and underestimation of strain
rate. However, we have carefully optimized the frame rate and
achieved an acceptable frame rate which is above the recommended
frame rate threshold for strain rate measurements.
Conclusions
In patients with varying degree of AS, severity, lower myocardial con-
tractility and higher arterial stiffness were both associated with lower
EF1, a marker of peak systolic function, independent of AS severity.
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Impact of Obesity on Persistent Left Ventricular
Hypertrophy After Aortic Valve Replacement
for Aortic Stenosis
Eigir Einarsen, MDa,*, Sahrai Saeed, MD, PhDb, Dana Cramariuc, MD, PhDb,
John B. Chambers, MD, PhDc, Helga Midtbø, MD, PhDb, and Eva Gerdts, MD, PhDa
Normalization of left ventricular (LV) hypertrophy is expected after successful aortic
valve replacement (AVR) in patients with aortic valve stenosis (AS), but is not always
observed. We tested the impact of body mass index (BMI) ≥30 kg/m2 on persistent
post-AVR LV hypertrophy. In the present subanalysis of Simvastatin Ezetimibe in
Aortic Stenosis study, clinical and echocardiographic data of 399 patients with severe
AS who underwent surgical AVR were analyzed. All patients had a standardized pre-
and post-AVR echocardiogram. Patients were grouped by BMI categories into BMI
<25 kg/m2, BMI 25 to 29.9 kg/m2, and BMI ≥30 kg/m2. LV hypertrophy was defined
as LV mass/height2.7 >49.2 g/m2.7 in men and >46.7 g/m2.7 in women. Predictors of
persistent LV hypertrophy after AVR were identified in logistic regression analysis.
After a median follow-up of 196 days after AVR, LV hypertrophy was more preva-
lent in patients with BMI ≥30 kg/m2 compared with those with BMI 25 to 29.9 kg/m2
and those patients with BMI <25 kg/m2 (71% vs 47% and 37%, p <0.01). BMI
≥30 kg/m2 patients also remained with lower LV midwall shortening post-AVR
compared with patients with normal weight (p <0.01), independent of patient pros-
thesis mismatch. In multivariable logistic regression analysis, the presence of BMI
≥30 kg/m2 before AVR was associated with an almost fourfold higher prevalence of
post-AVR LV hypertrophy independent of significant associations with higher systolic
blood pressure and lower LV midwall shortening preoperatively (odds ratio 3.75
[95% confidence interval 2.04 to 6.91], p <0.001). In conclusion, the presence of BMI
≥30 kg/m2 before AVR in patients with severe AS was strongly and independently
associated with persistent post-AVR LV hypertrophy. Crown Copyright © 2018
Published by Elsevier Inc. All rights reserved. (Am J Cardiol 2019;123:942−947)
Aortic valve stenosis (AS) is a progressive disease that
causes chronic pressure overload on the left ventricle, and
induces structural and functional changes in the left ventricu-
lar (LV) myocardium.1,2 Concomitant hypertension, obesity,
and metabolic syndrome have all been shown to increase
myocardial fibrosis and LV hypertrophy during progression
of AS.3−6 LV hypertrophy has been documented as an inde-
pendent risk factor for impaired prognosis both during AS
progression and after aortic valve replacement (AVR) in AS
patients.7−9 Following a successful AVR in AS patients,
regression of LV hypertrophy is expected but may not always
occur. Systemic hypertension and male gender have both
been associated with reduced post-AVR regression of LV
hypertrophy in AS patients.10−12 In smaller studies focusing
on the association of preoperative myocardial gene expres-
sion with post-AVR regression of LV hypertrophy, a negative
impact of higher preoperative body mass index (BMI) on the
postoperative LV hypertrophy regression was noted.13,14
However, the influence of BMI ≥30 kg/m2 on postoperative
LV hypertrophy regression in AS patients has not been
reported from larger clinical studies. Thus, the aim of the
present study was to assess the association of overweight
(BMI 25 to 29.9 kg/m2) and obesity (BMI ≥30 kg/m2) with
persistent post-AVR LV hypertrophy in symptomatic severe
AS patients treated with surgical AVR.
Methods
The present post hoc substudy was based on clinical and
echocardiographic data from patients enrolled in the large
prospective Simvastatin Ezetimibe in Aortic Stenosis
(SEAS) study who developed severe symptomatic AS dur-
ing the study follow-up period, and subsequently underwent
surgical AVR. The SEAS study was a randomized clinical
control trial investigating the effect of combined treatment
with Simvastatin 40 mg and ezetimibe 10 mg/day on pro-
gression of AS and associated cardiovascular events in
patients with initially mild-to-moderate AS. Patients with
preexisting coronary heart disease, heart failure, diabetes
mellitus, or other severe preexisting conditions were not
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included in the SEAS study.15 Ethical committees in all
participating countries approved the SEAS study protocol,
and patients signed written informed consent.16
Of the 1,873 patients enrolled in the SEAS study in
173 study centers within Europe, 545 patients underwent
surgical AVR. Among these, a post-AVR follow-up echo-
cardiogram was sent for blinded expert analysis at the
SEAS core echocardiography laboratory in Haukeland Uni-
versity Hospital, Bergen, Norway in 456 patients. In a total
of 57 patients, LV mass could not be assessed both on the
pre- and post-AVR echocardiograms due to poor image
quality in parasternal views. The remaining 399 patients
were included in the present analysis. Patients were
grouped according to BMI values measured at the pre-AVR
clinical visit into normal weight (BMI <25 kg/m2), over-
weight (BMI ≥25 kg/m2 and <30 kg/m2) and obesity (BMI
≥30 kg/m2). Hypertension was defined as a history of
hypertension, use of antihypertensive treatment, or clinical
brachial blood pressure ≥140/90 mm Hg measured at the
baseline clinical SEAS study visit.4
All echocardiograms used in the present study were first
read by the same junior investigator (EE), and later proof-
read by an experienced investigator (EG).15,16 Quantitative
assessment of LV structure and function and AS severity
was performed in accordance with current guidelines.1,17
LV hypertrophy was defined using the prognostically vali-
dated cut-off values LV mass/height2.7 >49.2 g/m2.7 in men
and >46.7 g/m2.7 in women.7 LV relative wall thickness
was calculated as posterior wall thickness £ 2/LV internal
diameter in end-diastole, and considered increased if
≥0.43. LV geometry was categorizing from LV relative
wall thickness and LV hypertrophy in combination, identi-
fying concentric remodeling as increased LV relative wall
thickness in patients with normal LV mass, and patients
with LV hypertrophy as having eccentric and concentric
hypertrophic patterns, respectively, depending on normal or
increased LV relative wall thickness. Severe patient pros-
thesis mismatch was defined as an indexed effective orifice
area ≤0.65 cm2/m2.18
Statistical analysis was performed using IBM SPSS ver-
sion 24.0 (IBM, Armonk, New York). Findings are reported
as mean with standard deviation for continuous variables and
as percentages for categorical variables. Analysis of variance
(ANOVA) with Scheffe’s post hoc test for continuous varia-
bles and Sidak post hoc test for categorical variables was
used to compare BMI groups, as appropriate. Covariates of
persistent LV hypertrophy at the post-AVR echocardiogram
were identified in uni- and multivariable logistic regression
analyses, and reported as odds ratio (OR) and 95% confi-
dence interval. A 2-tailed p value <0.05 was considered sta-
tistically significant in all analyses.
Results
Mean age in the total study population was 66 §
9 years and 64% were male. BMI groups did not differ
in blood pressure, age, or gender, but prevalence of
hypertension increased in parallel with BMI (Table 1).
The post-AVR echocardiogram was taken after a median
of 196 days (mean 208 § standard deviation 157 days).
The post-AVR follow-up time did not differ between
BMI groups. The prevalence of LV hypertrophy
decreased in all groups from the pre-AVR to the post-
AVR echocardiogram, but remained significantly higher
in patients with BMI ≥30 kg/m2 (p <0.01; Figure 1). In
particular, eccentric hypertrophy was more prevalent
among patients with BMI ≥30 kg/m2 at the post-AVR
echocardiogram (Table 2). Both patients with BMI 25 to
Table 1
Pre-AVR clinical characteristics of the BMI <25, BMI 25 to 29.9, and BMI ≥30 groups
Body mass index (kg/m2)
<25 25−29.9 ≥30 ANOVA p
Variable (n = 163) (n = 154) (n = 82)
Age (years) 67 § 10 65 § 9 65 § 9 0.052
Women 40% 34% 35% 0.525
Systolic blood pressure (mm Hg) 139 § 20 140 § 18 141 § 18 0.358
Diastolic blood pressure (mm Hg) 78 § 10 80 § 10 80 § 10 0.141
Heart rate (beats/min) 69 § 12 70 § 12 71 § 13 0.567
Body surface area (m2) 1.78 § 0.16 1.95 § 0.18* 2.01 §0.19*,y <0.001
BMI (kg/m2) 22.8 § 1.6 27.4 § 1.4* 33.3 § 3.1*,y <0.001
Height (meters) 1.71 § 0.1 1.72 § 0.1 1.70 § 0.1 0.243
Weight (kg) 68 § 10 81 § 11 95 § 14 <0.001
Hypertension 77% 84% 89% 0.043
Serum creatinine (mg/dl) 1.0 § 0.2 1.04 § 0.2 1.0 § 0.2 0.308
Total cholesterol (mg/dl) 181 § 54 185 § 54 178 § 46 0.586
HDL cholesterol (mg/dl) 66 § 15 58 § 15* 50 § 15*,y <0.001
LDL cholesterol (mg/dl) 101 § 50 104 § 50 101 § 46 0.376
Triglycerides (mg/dl) 88 § 35 106 § 53* 133 § 53*,y <0.001
Concomitant CAD requiring CABG 37% 30% 26% 0.185
Smoking 26% 21% 11%* 0.038
AVR = aortic valve replacement; BMI = body mass index; CABG = coronary artery bypass graft; CAD = coronary artery disease; HDL = high-density
lipoprotein; LDL = low-density lipoprotein.
* p <0.01 vs normal weight group.
y p <0.05 vs overweight group.
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29.9 kg/m2 and patients with BMI ≥30 kg/m2 had sig-
nificantly higher LV mass at the post-AVR echocardio-
gram compared with those with normal BMI. Patients
with BMI ≥30 kg/m2 also had significantly lower mid-
wall shortening compared with patients with normal
weight (Table 2). The mean change in LV mass after
AVR did not differ between groups (11% reduction in
the BMI ≥kg/m2 30 group, 10% reduction in the BMI
25 to 29.9 kg/m2 group and 10% reduction in the BMI
<25 kg/m2 group, p = 0.945). The prevalence of severe
patient prosthesis mismatch did not differ between BMI
groups (Table 2). The prevalence of persistent post-
AVR LV hypertrophy did not differ by gender (46.2%
for women and 48.8% for men, p = 0.67).
In univariable logistic regression analyses, persistent
post-AVR LV hypertrophy was significantly associated
with presence of BMI ≥30 kg/m2, lower midwall shorten-
ing, and higher systolic blood pressure (all p <0.05), but
not with gender, age, mean transprosthetic gradient, dura-
tion of days post-AVR follow-up echocardiography or pres-
ence of severe patient-prosthesis mismatch (all p >0.05;
Table 3). In a multivariable logistic regression analysis,
BMI ≥30 kg/m2, but not BMI 25 to 29.9 kg/m2, was associ-
ated with persistent post-AVR LV hypertrophy independent
of significant associations with higher pre-AVR systolic
blood pressure and lower midwall shortening (all p <0.05;
Table 3). Multicolinearity was ruled out in a parallel linear
regression model with post-AVR LV mass as a dependent
variable and including the same independent variables. All
variables had a high tolerance >0.96 and variance of infla-
tion factor was <1.1 for all variables. Replacing pre-AVR
with post-AVR BMI class in an alternative model yielded
similar results (data not shown).
Discussion
The present post hoc substudy from the SEAS study
focused on the impact of preoperative BMI ≥30 kg/m2 on
persistent LV hypertrophy after surgical AVR for severe
AS. As demonstrated, BMI ≥30 kg/m2 was strongly associ-
ated with LV hypertrophy and lower LV systolic myocar-
dial function postoperatively, even after adjustment for
important confounders including systolic blood pressure,
and lower midwall shortening. These findings add to previ-
ous knowledge focusing on the impact of obesity on LV
remodeling in preoperative studies in AS patients.3,5,6,19
Previous studies have documented the importance of LV
hypertrophy regression for long-term postoperative
prognosis.9,20 The present study expands previous findings
from smaller studies by documenting that BMI ≥30 kg/m2
may independently impair normalization of LV mass
during the first 6 months after surgical AVR for AS.13,14
Biederman et al demonstrated using cardiac magnetic reso-
nance imaging that although LV mass regression may con-
tinue up to 4 years after surgical AVR, it primarily
may occur within the first 6 postoperative months.21
Obesity is associated with cardiac steatosis and induces
LV hypertrophy through a number of hemodynamic and
nonhemodynamic mechanisms.22 In patients with AS, obe-
sity has been shown to increase myocardial fibrosis and
lead to more pathological remodeling during progression of
AS.3,6 The extent of myocardial fibrosis whether quantified
Figure 1. Prevalence of LV hypertrophy in obese, overweight, and normal weight groups at the pre- and post-AVR echocardiograms.
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by magnetic resonance imaging or histopathology has been
associated with less LV functional improvement as well as
increased late mortality after AVR for AS.23 A nonlinear
relation with BMI and 30-day and long-term mortality was
reported by Roberts et al, demonstrating that patients
treated with AVR for AS with BMI >40 kg/m2 and in the
mid-20s had significantly higher mortality rates compared
with patients with BMI in the early 30s.24 Recently, it was
demonstrated by cardiac magnetic resonance spectroscopy
also that severe AS is associated with myocardial
steatosis.25 This cardiac steatosis may saturate the beta-oxi-
dative system, and fatty acids may by nonoxidative path-
ways lead to myocardial fibrosis and altered myocardial
structure and function.6 While post-AVR pressure-overload
relief leads to reduction of the cardiomyocyte hypertrophy,
nonmuscular myocardial components, including the obesity
associated interstitial fat infiltration and accumulation
of triglycerides in the contractile elements, will not be
reduced, leading to persistent LV hypertrophy in these
patients, as demonstrated by the present findings.22 Our
findings are in line with a recent report by Treibel et al dem-
onstrating by cardiac magnetic resonance imaging that
post-AVR regress of nonmuscular myocardial LVH in AS
mainly took place after the first 6 postoperative months.26
In the SEAS-study, BMI ≥30 kg/m2 was associated with
higher LV mass, LV systolic dysfunction, and increased
mortality during progression of AS.3,19 The Aortic Stenosis
Progression Observation Measuring Effects of Rosuvastatin
study also linked obesity and metabolic syndrome with
presence of impaired LV diastolic and systolic function,
and reported that patients with obesity had significantly
more concentric LV hypertrophy.5 In contrast, BMI
≥30 kg/m2 was particularly associated with persistent
eccentric LV hypertrophy in the present post-AVR study.
The contrasting findings may reflect that AVR effectively
reduce pressure overload caused by the valvular obstruction
in AS, whereas LV effects of concomitant obesity or hyper-
tension are not influenced. Our findings expand previous
knowledge by demonstrating the influence of BMI ≥30 on
persistent LV hypertrophy and myocardial LV dysfunction
after surgical AVR for severe AS.
Previous data from our group demonstrated that uncon-
trolled hypertension is associated with lack of improvement
in postoperative exercise capacity in AS patients.10
Imanaka et al also reported the importance of postoperative
blood pressure control on regression of LV mass.27 In the
present study, no association between hypertension and
post-AVR LV hypertrophy was found, but higher pre-AVR
systolic blood pressure was associated with persistent
post-AVR LV hypertrophy independent of presence of
BMI ≥30 kg/m2.
Prosthesis-patient mismatch is commonly found after
surgical AVR for AS and associated with impaired post-
AVR LV hypertrophy regression and prognosis, in particu-
lar in patients with impaired preoperative LV function.18,28
In the present study, the prevalence severe prosthesis-
patient mismatch did not differ between groups, and no
significant association with persistent post-AVR LV hyper-
trophy was found.
Circulating female estrogens have been proposed to
influence micro ribonucleic acid expression in collagens
synthesis,29 explaining the previous reported gender differ-
ence in LV remodeling during progression of AS.2 In the
present study, no association between gender and persistent
post-AVR LV hypertrophy was observed, in line with pre-
vious findings by Dobson et al assessing LV structure by
cardiac magnetic resonance imaging.30 In contrast, among
AS patients treated with transcatheter AVR (TAVR) in the
PARTNER (Placement of Aortic Transcatheter Valves)
study, women were reported to have significantly better
post-TAVR reduction in LV mass compared with men
which translated into lower incidence of rehospitalization
for heart failure.12 However, the majority of these patients
had persistent LV hypertrophy at the 30-day post-TAVR
echocardiogram.
In conclusion, the present findings expand current
knowledge by demonstrating that preoperative BMI ≥30 in
AS patients without known diabetes or cardiovascular
disease is an independent and important contributor for
persistent post-AVR LV hypertrophy.
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Table 3
Impact of BMI ≥30 on persistent post-AVR LV hypertrophy, uni- and multivariable logistic regression analyses
Univariable Multivariable
Variable OR (95% CI) p OR (95% CI) p
BMI ≥ 30 4.18 (2.32-7.52) < 0.001 3.75 (2.04-6.91) <0.001
BMI 25-29.9 1.48 (0.95-2.33) 0.086 1.47 (0.93-2.35) 0.102
Pre-AVR systolic blood pressure (mm Hg) 1.02 (1.01-1.03) 0.003 1.02 (1.01-1.03) 0.003
Pre-AVR midwall shortening 0.89 (0.83-0.96) 0.002 0.90 (0.83-0.97) 0.008
Baseline hypertension 1.47 (0.87-2.49) 0.149
Post-AVR days 1.00 (0.99-1.00) 0.963
Mean trans-prosthetic gradient (mm Hg) 1.02 (0.98-1.07) 0.256
Age (years) 1.00 (0.98-1.02) 0.965
Men 1.11 (0.74-0.68) 0.615
Severe patient prosthesis mismatch 0.66 (0.38-1.14) 0.133
BMI = body mass index.
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